85. 特発性間質性肺炎 Disease details / Clinical trials / Drug dev / DR info

18F-FDG
   Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui
      2007   -   JPRN-UMIN000010498   Japan
20MM sodium pyruvate nasal spray
   Cellular Sciences, inc.
      2023   Phase 3   NCT06037408   United States
3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt
   Vicore Pharma AB
      2020   Phase 2   EUCTR2020-000822-24-GB   Ukraine;United Kingdom
534-1508
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 4   EUCTR2015-003280-11-IT   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
   F. Hoffmann-La Roche Ltd
      2016   Phase 4   EUCTR2015-003280-11-NL   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2016   Phase 4   EUCTR2015-003280-11-DK   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2016   Phase 4   EUCTR2015-003280-11-DE   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
   Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
      2015   Phase 4   EUCTR2015-003280-11-ES   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
60% oxygen
   University of British Columbia
      2015   -   NCT02551068   Canada
68GA-BMV101
   Peking Union Medical College Hospital
      2015   Early Phase 1   NCT02485886   China
9mw3811 injection
   Mabwell (Shanghai) Bioscience Co., Ltd.
      2023   Phase 1   NCT05912049   China
Acetylcysteine
   Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine
      2017   Phase 0   ChiCTR2200058641   China
   Shanghai Pulmonary Hospital, Tongji University School of Medicine
      2020   -   ChiCTR2000031386   China
ACT-064992
   ACTELION Pharmaceuticals Ltd.
      2011   Phase 2   EUCTR2010-024211-13-SI   Australia;Canada;Germany;Israel;Slovenia;South Africa;Spain;Sweden;Turkey;United States
      2011   Phase 2   EUCTR2010-024211-13-SE   Australia;Canada;Germany;Israel;Slovenia;South Africa;Spain;Sweden;Turkey;United States
      2011   Phase 2   EUCTR2010-024211-13-ES   Australia;Canada;Germany;Israel;Slovenia;South Africa;Spain;Sweden;Turkey;United States
      2011   -   EUCTR2010-024211-13-DE   Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States
   Actelion
      2009   Phase 2   NCT00903331   Australia;Canada;France;Germany;Israel;Italy;Slovenia;South Africa;Spain;Sweden;Turkey;United States
   Actelion Pharamceuticals Ltd
      2010   -   EUCTR2008-006054-17-IT   France;Germany;Italy;Slovenia;Spain;Sweden
   Actelion Pharmaceuticals Ltd.
      2009   -   EUCTR2008-006054-17-SI   France;Germany;Italy;Slovenia;Spain;Sweden
      2009   -   EUCTR2008-006054-17-SE   France;Germany;Italy;Slovenia;Spain;Sweden
      2009   Phase 2   EUCTR2008-006054-17-FR   France;Germany;Italy;Slovenia;Spain;Sweden
      2009   Phase 2   EUCTR2008-006054-17-ES   France;Germany;Italy;Slovenia;Spain;Sweden
      -   -   EUCTR2008-006054-17-DE   France;Germany;Italy;Slovenia;Spain;Sweden
Activated charcoal
   Center for Clinical Pharmacology, the Third Xiangya Hospital of Central South University
      2022   Phase 1   ChiCTR2200064910   China
Adult human mesenchymal stem cells
   Joshua M Hare
      2013   Phase 1   NCT02013700   United States
Aerosol interferon-gamma
   NYU Langone Health
      2007   Phase 1   NCT00563212   United States
AGMB-447
   Agomab Spain S.L.
      2023   Phase 1   NCT06181370   United Kingdom
AIR
   Department of Respiratory Medicine and Allergology, Kinki University School of Medicine
      2011   -   JPRN-UMIN000005098   Japan
   Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.
      2015   -   JPRN-UMIN000015508   Japan
   Tosei General Hospital
      2009   -   JPRN-UMIN000025256   Japan
Alemtuzumab
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States
Allorx
   The Foundation for Orthopaedics and Regenerative Medicine
      2022   Phase 1   NCT05016817   Antigua and Barbuda;Argentina;Mexico
AMB-05X
   AmMax Bio, Inc.
      2023   Phase 2   NCT05349760   -
Ambrisentan
   Gilead Sciences
      2009   Phase 3   NCT00879229   Australia;Austria;Belgium;Canada;Germany;Ireland;Israel;Italy;United Kingdom;United States
      2008   Phase 3   NCT00768300   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;France;Germany;Ireland;Israel;Italy;Mexico;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
   Gilead Sciences Incorporated
      2010   -   EUCTR2008-004405-34-CZ   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-004405-34-NL   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-IT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-GB   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-004405-34-FR   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-ES   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-BE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-AT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      -   -   EUCTR2008-004405-34-DE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
   Gilead Sciences, Inc
      2009   -   EUCTR2009-011169-98-GB   Austria;Czech Republic;Germany;Italy;United Kingdom
      2009   -   EUCTR2009-011169-98-DE   Austria;Czech Republic;Germany;Italy;United Kingdom
      2009   -   EUCTR2009-011169-98-AT   Austria;Czech Republic;Germany;Italy;United Kingdom
   Gilead Sciences, Inc.
      2011   -   EUCTR2009-011169-98-CZ   Austria;Czech Republic;Germany;Italy;United Kingdom
ANG-3070
   Angion Biomedica Corp
      2022   Phase 1   NCT05387785   -
Anlotinib
   First Affiliated Hospital of Wenzhou Medical University
      2021   Phase 2/Phase 3   NCT05828953   China
Anticorpo monoclonale antagonista DEL fattore xiia
   CSL Behring Innovation GmbH
      2022   Phase 2   EUCTR2021-003162-12-IT   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Latvia;Lithuania;Norway;Poland;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States
Antimicrobial therapy: CO-trimoxazole or doxycycline
   Weill Medical College of Cornell University
      2017   Phase 3   NCT02759120   United States
AP01
   Avalyn Pharma, Inc.
      2021   Phase 2   EUCTR2020-005103-39-PL   Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom
      2021   Phase 2   EUCTR2020-005103-39-NL   Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom
      2021   Phase 2   EUCTR2020-005103-39-CZ   Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom
ARO-MMP7 inhalation solution
   Arrowhead Pharmaceuticals
      2023   Phase 1/Phase 2   NCT05537025   Denmark;Italy;Korea, Republic of;New Zealand;Spain;United Kingdom
ART-123
   ASAHI KASEI PHARMA CORPORATION
      2016   Phase 3   JPRN-jRCT2080223271   Japan
   Asahi Kasei Pharma Corporation
      2016   Phase 3   NCT02739165   Japan
Artesunate oral product
   Joseph C. Wu
      2025   Phase 1   NCT05988463   United States
Atezolizumab
   Cedars-Sinai Medical Center
      2023   Phase 1   NCT05515627   United States
   KATO Terufumi
      2019   Phase 2   JPRN-jRCTs031190084   -
AUTO-titrating oxygen system
   Imperial College London
      2014   -   NCT02248064   United Kingdom
Autoantibody reductive therapy
   University of Alabama at Birmingham
      2018   Phase 2   NCT03286556   United States
Autologous mesenchymal stem cells derived from bone marrow
   Clinica Universidad de Navarra, Universidad de Navarra
      2013   Phase 1   NCT01919827   Spain
Axatilimab
   Syndax Pharmaceuticals
      2023   Phase 2   NCT06132256   Australia;Belgium;Canada;Czechia;France;Germany;Italy;Korea, Republic of;Poland;Spain;Taiwan;United Kingdom
Azapred
   Thorax National Institute
      2005   -   NCT00518310   Chile
Azathioprine
   InterMune
      2002   Phase 3   NCT00052039   Italy
Azathioprine/prednisone
   University of Michigan
      2001   Phase 2   NCT00262405   United States
AZD5055
   AstraZeneca
      2021   Phase 1   NCT05134727   United States
Azithromycin
   Assiut University
      2023   -   NCT05842681   Egypt
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada
   Tongren Hospital, Shanghai Jiao Tong University School of Medicine
      2024   -   ChiCTR2400084928   China
   University Hospital Inselspital, Berne
      2014   -   NCT02173145   Switzerland
Bardoxolone methyl
   Reata, a wholly owned subsidiary of Biogen
      2014   Phase 2   NCT02036970   Germany;Spain;United Kingdom;United States
BBT-877
   Bridge Biotherapeutics, Inc.
      2023   Phase 2   NCT05483907   Australia;Israel;Korea, Republic of;Poland;United States
BBT-877, multiple doses
   Bridge Biotherapeutics, Inc.
      2019   Phase 1   NCT03830125   United States
BBT-877, single dose
   Bridge Biotherapeutics, Inc.
      2019   Phase 1   NCT03830125   United States
Beclometasone dipropionate
   Hull and East Yorkshire Hospitals NHS Trust
      2014   -   EUCTR2013-004404-19-GB   United Kingdom
Belumosudil
   Kadmon Corporation, LLC
      2016   Phase 2   NCT02688647   United States
Bevacizumab
   IP lung cancer study group
      2012   -   JPRN-UMIN000018322   Japan
   Katakami Nobuyuki
      2013   Phase 2   JPRN-jRCTs061180046   -
BG00011
   BIOGEN IDEC RESEARCH LIMITED
      2018   Phase 2   EUCTR2017-003158-18-IT   Argentina;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
   Biogen
      2018   Phase 2   NCT03573505   Argentina;Australia;Belgium;Chile;Czechia;Denmark;France;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2012   Phase 2   NCT01371305   United States
   Biogen Idec Research Limited
      2019   Phase 2   EUCTR2017-003158-18-PL   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2017-003158-18-DE   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-NL   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-GR   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-GB   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-ES   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-DK   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-CZ   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-BE   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
BI 1015550
      2020   Phase 2   EUCTR2019-004167-45-GR   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2022   Phase 3   EUCTR2022-001091-34-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004167-45-IT   Australia;Austria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
   Boehringer Ingelheim
      2025   Phase 2   NCT06241560   Georgia
      2024   Phase 3   NCT06238622   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   NCT05321069   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Serbia;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2020   Phase 2   NCT04419506   Argentina;Australia;Austria;Canada;Chile;China;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004167-45-NL   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2018   Phase 1   NCT03422068   Belgium;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;United Kingdom
   Boehringer Ingelheim B.V.
      2020   Phase 2   EUCTR2019-004167-45-DK   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
   Boehringer Ingelheim Finland Ky
      2020   Phase 2   EUCTR2019-004167-45-FI   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
   Boehringer Ingelheim Limited
      2020   Phase 2   EUCTR2019-004167-45-GB   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2020   Phase 2   EUCTR2019-004167-45-DE   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
   Boehringer Ingelheim RCV GmbH & Co KG
      2021   Phase 2   EUCTR2019-004167-45-CZ   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004167-45-SK   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004167-45-PL   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004167-45-HU   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004167-45-AT   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
   Igarashi Haruki
      2024   Phase 3   JPRN-jRCT2021240008   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Estonia;Ezypt;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea;Malaysia;Mexico;Netherlands;NewZealand;Norway;Poland
   Saito Isao
      2022   Phase 3   JPRN-jRCT2031220317   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czech Republicc;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hangary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexco;Nerherland;New Zealand;Poland;Republic of Korea;United States
BI 1015550 18 MG film coated tablet
   Boehringer Ingelheim AB
      2022   Phase 3   EUCTR2022-001091-34-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Boehringer Ingelheim B.V
      2022   Phase 3   EUCTR2022-001091-34-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
   Boehringer Ingelheim B.V.
      2023   Phase 3   EUCTR2022-001091-34-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Türkiye;United Kingdom;United States
   Boehringer Ingelheim BV Netherlands
      2022   Phase 3   EUCTR2022-001091-34-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Türkiye;United Kingdom;United States
   Boehringer Ingelheim France
      2022   Phase 3   EUCTR2022-001091-34-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001091-34-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Türkiye;United Kingdom;United States
   Boehringer Ingelheim International GmbH
      2022   Phase 3   EUCTR2022-001091-34-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
   Boehringer Ingelheim Norway KS
      2022   Phase 3   EUCTR2022-001091-34-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2022   Phase 3   EUCTR2022-001091-34-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Türkiye;United Kingdom;United States
   Boehringer Ingelheim Portugal
      2023   Phase 3   EUCTR2022-001091-34-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Boehringer Ingelheim RCV GmbH & Co KG
      2023   Phase 3   EUCTR2022-001091-34-SI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001091-34-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001091-34-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Boehringer Ingelheim SComm
      2023   Phase 3   EUCTR2022-001091-34-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
   Boehringer-Ingelheim B.V.
      2022   Phase 3   EUCTR2022-001091-34-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Türkiye;United Kingdom;United States
BI 1015550 9 MG film coated tablet
   Boehringer Ingelheim AB
      2022   Phase 3   EUCTR2022-001091-34-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Boehringer Ingelheim B.V
      2022   Phase 3   EUCTR2022-001091-34-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
   Boehringer Ingelheim B.V.
      2023   Phase 3   EUCTR2022-001091-34-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Türkiye;United Kingdom;United States
   Boehringer Ingelheim BV Netherlands
      2022   Phase 3   EUCTR2022-001091-34-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Türkiye;United Kingdom;United States
   Boehringer Ingelheim France
      2022   Phase 3   EUCTR2022-001091-34-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001091-34-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Türkiye;United Kingdom;United States
   Boehringer Ingelheim International GmbH
      2022   Phase 3   EUCTR2022-001091-34-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
   Boehringer Ingelheim Norway KS
      2022   Phase 3   EUCTR2022-001091-34-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2022   Phase 3   EUCTR2022-001091-34-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Türkiye;United Kingdom;United States
   Boehringer Ingelheim Portugal
      2023   Phase 3   EUCTR2022-001091-34-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Boehringer Ingelheim RCV GmbH & Co KG
      2023   Phase 3   EUCTR2022-001091-34-SI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001091-34-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001091-34-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Boehringer Ingelheim SComm
      2023   Phase 3   EUCTR2022-001091-34-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
   Boehringer-Ingelheim B.V.
      2022   Phase 3   EUCTR2022-001091-34-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Türkiye;United Kingdom;United States
BI 1819479
   Boehringer Ingelheim
      2024   Phase 2   NCT06335303   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Malaysia;New Zealand;Norway;Poland;Singapore;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States
BI 1839100
   Boehringer Ingelheim
      2024   Phase 2   NCT06360094   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Singapore;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States
Bibf 1120
   BOEHRINGER ING.
      2012   Phase 3   EUCTR2011-002766-21-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-024251-87-IT   Belgium;Czech Republic;Germany;Ireland;Italy;United Kingdom
      2010   Phase 2   EUCTR2009-013788-21-IT   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2015   Phase 4   EUCTR2015-000640-42-IT   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim
      2012   Phase 3   NCT01619085   Australia;Belgium;Canada;Chile;China;Czech Republic;Czechia;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2012   Phase 3   EUCTR2011-002766-21-FI   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2011   Phase 3   NCT01335477   Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States
      2011   Phase 3   NCT01335464   Argentina;Australia;Belgium;Brazil;China;Czech Republic;France;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States
      2011   -   EUCTR2010-024252-29-NL   Finland;Germany;Greece;Netherlands;Portugal;Spain
      2011   -   EUCTR2010-024252-29-GR   Finland;Germany;Greece;Netherlands;Portugal;Spain
      2011   -   EUCTR2010-024252-29-FI   Finland;Germany;Greece;Netherlands;Portugal;Spain
      2010   Phase 2   NCT01170065   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Russian Federation;Spain;United Kingdom
      2010   Phase 2   NCT01136174   Japan
      2008   -   EUCTR2006-002875-42-GR   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-002875-42-IE   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
      2007   Phase 2   EUCTR2006-002875-42-GB   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-002875-42-DE   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
   Boehringer Ingelheim Hellas
      2012   Phase 3   EUCTR2011-002766-21-GR   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Boehringer Ingelheim Ellas AE
      2010   -   EUCTR2009-013788-21-GR   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom
   Boehringer Ingelheim España S.A
      2012   Phase 3   EUCTR2011-002766-21-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Boehringer Ingelheim España S.A.
      2010   -   EUCTR2009-013788-21-ES   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom
   Boehringer Ingelheim España, S.A.
      2011   Phase 3   EUCTR2010-024252-29-ES   Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States
      2007   -   EUCTR2006-002875-42-ES   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
   Boehringer Ingelheim France
      2011   -   EUCTR2010-024252-29-PT   Canada;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;United States
      2010   Phase 2   EUCTR2009-013788-21-FR   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom
      2008   -   EUCTR2006-002875-42-PT   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
   Boehringer Ingelheim France SAS
      2007   Phase 2   EUCTR2006-002875-42-FR   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
   Boehringer Ingelheim Limited
      2013   Phase 3   EUCTR2011-002766-21-IE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2012   Phase 3   EUCTR2011-002766-21-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-024251-87-IE   Belgium;Czech Republic;Germany;Ireland;Italy;United Kingdom
      2011   Phase 3   EUCTR2010-024251-87-GB   Belgium;Czech Republic;Germany;Ireland;Italy;United Kingdom
      2010   Phase 2   EUCTR2009-013788-21-GB   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom
   Boehringer Ingelheim Ltd
      2010   Phase 2   EUCTR2009-013788-21-IE   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom
   Boehringer Ingelheim Pharma Ges mbH
      2008   -   EUCTR2006-002875-42-BG   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-002875-42-CZ   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2012   Phase 3   EUCTR2011-002766-21-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-024252-29-DE   Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States
      2011   -   EUCTR2010-024251-87-DE   Argentina;Australia;Belgium;Brazil;China;Czech Republic;France;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States
      2010   Phase 2   EUCTR2009-013788-21-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;United Kingdom
   Boehringer Ingelheim RCV Ges mbH & Co KG
      2007   -   EUCTR2006-002875-42-HU   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
   Boehringer Ingelheim RCV GmBH & Co KG
      2011   -   EUCTR2010-024251-87-CZ   Argentina;Australia;Belgium;Brazil;China;Czech Republic;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States
      2010   Phase 2   EUCTR2009-013788-21-HU   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom
      2010   -   EUCTR2009-013788-21-BG   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom
   Boehringer Ingelheim RCV GmbH & Co KG
      2012   Phase 3   EUCTR2011-002766-21-CZ   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2010   Phase 2   EUCTR2009-013788-21-CZ   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Russian Federation;Spain;United Kingdom
   Boehringer Ingelheim bv
      2007   -   EUCTR2006-002875-42-NL   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
   SCS Boehringer Ingelheim Comm.V
      2011   Phase 3   EUCTR2010-024251-87-BE   Argentina;Australia;Belgium;Brazil;China;Czech Republic;France;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States
      2010   Phase 2   EUCTR2009-013788-21-BE   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-002875-42-BE   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
   SCS Boehringer Ingelheim Ingelheim Comm.V
      2012   Phase 3   EUCTR2011-002766-21-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
      2012   Phase 3   EUCTR2011-002766-21-PT   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Unilfarma, Lda.
      2010   Phase 2   EUCTR2009-013788-21-PT   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom
Bibf 1120 ES
   BOEHRINGER ING.
      2007   -   EUCTR2006-002875-42-IT   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom
BIBF1120
   Boehringer Ingelheim España, S.A.
      2011   Phase 3   EUCTR2010-024252-29-ES   Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States
BLD-0409
   Blade Therapeutics
      2022   Phase 2   NCT05373914   -
BLD-2660
   Blade Therapeutics
      2019   Phase 2   NCT04244825   United Kingdom
   Blade Therapeutics, Inc.
      2020   Phase 2   EUCTR2019-004998-34-GB   United Kingdom
Blood sample collection
   Center for Clinical Pharmacology, the Third Xiangya Hospital of Central South University
      2022   Phase 1   ChiCTR2200064910   China
   Rennes University Hospital
      2014   -   NCT04016168   France
BMS-986020
   Bristol-Myers Squibb
      2013   Phase 2   NCT01766817   Australia;Chile;Colombia;Mexico;Peru;United States
BMS-986278
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2020   Phase 2   EUCTR2019-003992-21-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States
   Bristol-Myers Squibb
      2023   Phase 3   NCT06003426   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Puerto Rico;Spain;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
      2019   Phase 1   NCT03981094   United States
   Bristol-Myers Squibb International Corporation
      2020   Phase 2   EUCTR2019-003992-21-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States
   Wang Yan
      2023   Phase 3   JPRN-jRCT2021230026   Japan;US
Bone marrow mesenchymal stem cells
   Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
      2013   Phase 1/Phase 2   NCT02594839   Russian Federation
Bosentan
   ACTELION PHARMACEUTICALS LTD
      2007   Phase 3   EUCTR2006-001183-24-SK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-IE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-001183-24-GB   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-001183-24-ES   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-DK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-DE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-CZ   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-AT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2006   -   EUCTR2006-001183-24-BE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      -   Phase 3   EUCTR2006-001183-24-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
   Actelion
      2008   Phase 3   NCT00631475   Australia;Austria;Belgium;Canada;Croatia;Czech Republic;Former Serbia and Montenegro;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Serbia;Spain;Switzerland;United Kingdom;United States
      2007   Phase 3   NCT00391443   Australia;Austria;Belgium;Canada;Croatia;Czech Republic;Denmark;Former Serbia and Montenegro;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Serbia;Slovakia;Spain;Switzerland;United Kingdom;United States
      2003   Phase 2/Phase 3   NCT00071461   Canada;France;Germany;Israel;Italy;Switzerland;United Kingdom;United States
   Actelion Pharmaceuticals Ltd
      2009   -   EUCTR2007-001741-18-AT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-NL   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-001741-18-GB   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-001741-18-FR   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-ES   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-DE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-CZ   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-BE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
   Actelion Registration Ltd
      2008   -   EUCTR2007-001741-18-IT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
   Rajan Saggar
      2007   Phase 4   NCT00625469   United States
   Royal Brompton & Harefield NHS Foundation Trust
      2008   Phase 4   NCT00637065   United Kingdom
Broncho-vaxom
   Shanghai Pulmonary Hospital
      2015   -   ChiCTR-OOC-15005840   China
BSC
   Kadmon Corporation, LLC
      2016   Phase 2   NCT02688647   United States
Buloxibutid
   Vicore Pharma AB
      2024   Phase 2   NCT06588686   Argentina;Australia;Austria;Belgium;Canada;Germany;Greece;Italy;Korea, Republic of;Mexico;Poland;Taiwan;United Kingdom;United States
C106 solution
   Vicore Pharma AB
      2022   Phase 1   NCT05427253   Sweden
C21
   Vicore Pharma AB
      2020   Phase 2   NCT04533022   India;Russian Federation;Ukraine;United Kingdom
      2020   Phase 2   EUCTR2020-000822-24-GB   Ukraine;United Kingdom
      2018   Phase 2   EUCTR2017-004923-63-GB   Bulgaria;Poland;Serbia;United Kingdom
CAL101
   Calluna Pharma AS
      2025   Phase 2   NCT06736990   -
Carboplatin
   Fujimoto Daichi
      2021   -   JPRN-jRCTs051200109   -
   Hirosaki University Graduate School of Medicine
      2016   -   JPRN-UMIN000021591   Japan
   IKEDA Satoshi
      2019   Phase 2   JPRN-jRCTs031190119   -
   IP lung cancer study group
      2012   -   JPRN-UMIN000018322   Japan
      2012   -   JPRN-UMIN000018248   Japan
   Katakami Nobuyuki
      2013   Phase 2   JPRN-jRCTs061180046   -
      2013   Phase 2   JPRN-jRCTs051180149   -
   Lung Oncology Group in Kyushu, Japan (LOGIK)
      2007   -   JPRN-UMIN000015929   Japan
   Okamoto Isamu
      2017   Phase 3   JPRN-jRCTs071180049   -
   Research Institute for Diseases of the Chest, Kyushu University
      2017   Phase 3   JPRN-UMIN000026799   Japan
Cbdca
   Lung Oncology Group in Kyushu, Japan (LOGIK)
      2007   -   JPRN-UMIN000015929   Japan
CC-90001
   Celgene
      2017   Phase 2   NCT03142191   Australia;Brazil;Canada;China;Colombia;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;Ukraine;United Kingdom;United States
   Celgene Corporation
      2017   Phase 2   EUCTR2016-003473-17-GR   Australia;Brazil;Canada;Colombia;France;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003473-17-GB   Australia;Brazil;Canada;Colombia;France;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States
CC-930
   Celgene
      2011   Phase 2   NCT01203943   Canada;United States
CD3/CD19 negative hematopoietic stem cells
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States
Centricyte 1000
   Black Tie Medical, Inc.
      2020   Early Phase 1   NCT04326036   United States
CHF10067 high dose
   Chiesi Farmaceutici S.p.A.
      2023   Phase 1   NCT05513950   North Macedonia;Ukraine;United Kingdom
CHF10067 intermediate dose
   Chiesi Farmaceutici S.p.A.
      2023   Phase 1   NCT05513950   North Macedonia;Ukraine;United Kingdom
CHF10067 starting dose
   Chiesi Farmaceutici S.p.A.
      2023   Phase 1   NCT05513950   North Macedonia;Ukraine;United Kingdom
CMR316
   Calibr, a division of Scripps Research
      2024   Phase 1   NCT06589219   Germany
Cnto 888 1 MG/KG
   Centocor, Inc.
      2008   Phase 2   NCT00786201   Belgium;Canada;Germany;Netherlands;United States
Cnto 888 15 MG/KG
   Centocor, Inc.
      2008   Phase 2   NCT00786201   Belgium;Canada;Germany;Netherlands;United States
Cnto 888 5 MG/KG
   Centocor, Inc.
      2008   Phase 2   NCT00786201   Belgium;Canada;Germany;Netherlands;United States
CNTO888
   Centocor B.V.
      2009   -   EUCTR2008-001281-86-NL   Belgium;Germany;Netherlands
   Janssen Biologics B.V.
      2010   -   EUCTR2008-001281-86-DE   Belgium;Germany;Netherlands
      2009   Phase 2   EUCTR2008-001281-86-BE   Belgium;Germany;Netherlands
CO-trimoxazole
   University of East Anglia
      2007   -   EUCTR2007-002324-15-GB   United Kingdom
Combined plasma exchange (PEX), rituximab, and corticosteroids
   Michael Donahoe
      2011   Phase 1/Phase 2   NCT01266317   United States
Compound 21
   Vicore Pharma AB
      2018   Phase 2   EUCTR2017-004923-63-GB   Bulgaria;Poland;Serbia;United Kingdom
Computer-assisted telephone interview
   Imperial College London
      2017   -   NCT03211507   United Kingdom
Cotrimoxazole
   Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
      2013   Phase 3   NCT01777737   Spain
   Norfolk and Norwich University Hospital NHS Foundation Trust
      2014   Phase 3   EUCTR2014-004058-32-GB   United Kingdom
Cough monitor
   Erasmus Medical Center
      2013   -   NCT02009293   France;Italy;Netherlands
Cromoglicato disodico
   Respivant Sciences, GmbH
      2019   Phase 2   EUCTR2018-004447-23-IT   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
Cromoglycate
   Patara Pharma
      2015   -   EUCTR2014-004025-40-NL   Netherlands;United Kingdom
      2014   Phase 2   EUCTR2014-004025-40-GB   Netherlands;United Kingdom
   Respivant Sciences GmbH
      2019   Phase 2   EUCTR2018-004447-23-NL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-GB   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-DE   Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-BE   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
Cromolyn
   Respivant Sciences, GmbH
      2019   Phase 2   EUCTR2018-004447-23-IT   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
Cromolyn sodium
   Patara Pharma
      2015   -   EUCTR2014-004025-40-NL   Netherlands;United Kingdom
      2014   Phase 2   EUCTR2014-004025-40-GB   Netherlands;United Kingdom
   Respivant Sciences GmbH
      2019   Phase 2   EUCTR2018-004447-23-NL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-GB   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-DE   Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-BE   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
   University of California, San Francisco
      2015   Phase 1   NCT01841307   United States
CSL312
   CSL Behring
      2022   Phase 2   NCT05130970   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Poland;Spain;United Kingdom;United States
CSL312 garadacimab
   CSL Behring Innovation GmbH
      2022   Phase 2   EUCTR2021-003162-12-IT   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Latvia;Lithuania;Norway;Poland;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States
   CSL Behring LLC
      2022   Phase 2   EUCTR2021-003162-12-PL   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003162-12-DK   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003162-12-DE   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003162-12-BE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003162-12-AT   Australia;Austria;Belgium;Canada;Czechia;Denmark;Germany;Italy;Poland;Spain;United Kingdom;United States
Cudetaxestat
   Blade Therapeutics
      2022   Phase 2   NCT05373914   -
Cyclosphamine
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2015   Phase 3   EUCTR2015-000492-27-FR   France
Dabigatran
   University College, London
      2016   -   NCT02885961   -
Dasatinib + quercetin
   Wake Forest University Health Sciences
      2016   Phase 1   NCT02874989   United States
Delivery OF 99MTC-dtpa aerosol
   University Hospital, Tours
      2022   -   NCT05366387   France
Deupirfenidone
   PureTech
      2022   Phase 2   NCT05321420   Argentina;Chile;Colombia;Georgia;Greece;India;Korea, Republic of;Malaysia;Mexico;Philippines;Romania;South Africa;Thailand;United States
   PureTech LYT 100, Inc.
      2022   Phase 2   EUCTR2021-006820-41-RO   Argentina;Chile;Colombia;Georgia;Greece;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Serbia;South Africa;Thailand;United States
      2022   Phase 2   EUCTR2021-006820-41-GR   Argentina;Chile;Colombia;Georgia;Greece;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;South Africa;Thailand;United States
DEX284
   Galecto Biotech AB
      2020   Phase 2   EUCTR2018-002664-73-IE   Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002664-73-PL   Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002664-73-IT   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002664-73-GB   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002664-73-FR   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002664-73-ES   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
Dextromethorphan
   Tianjin Medical University General Hospital
      2020   Phase 4   ChiCTR2000037602   China
Diet A group
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04767815   Korea, Republic of
Diet B group
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04767815   Korea, Republic of
Diet C group
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04767815   Korea, Republic of
Digital lung sounds auscultation
   Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      2024   -   NCT06521125   -
DNA sequencing
   Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      2024   -   NCT06521125   -
DRY powder inhaler
   Rein Therapeutics
      2025   Phase 2   NCT06968845   United States
Durvalumab
   Fujimoto Daichi
      2021   -   JPRN-jRCTs051200109   -
DWN12088
   Daewoong Pharmaceutical Co. LTD.
      2022   Phase 2   NCT05389215   Korea, Republic of;United States
      2021   Phase 1   NCT04888728   Korea, Republic of
      2021   Phase 1   NCT04888715   Korea, Republic of
Egcg
   Hal Chapman
      2017   Early Phase 1   NCT03928847   United States
Egcg 300 MG
   Hal Chapman
      2024   Phase 1   NCT06265532   United States
Egcg 300 MG + nintedanib
   Hal Chapman
      2023   Phase 1   NCT05195918   United States
Egcg 300 MG + pirfenidone
   Hal Chapman
      2023   Phase 1   NCT05195918   United States
Egcg 600 MG
   Hal Chapman
      2024   Phase 1   NCT06265532   United States
Egcg 600 MG + nintedanib
   Hal Chapman
      2023   Phase 1   NCT05195918   United States
Egcg 600 MG + pirfenidone
   Hal Chapman
      2023   Phase 1   NCT05195918   United States
Endobronchial infusion OF adult mesenchymal stem cells
   Clinica Universidad de Navarra, Universidad de Navarra
      2013   Phase 1   NCT01919827   Spain
Endoxan
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2015   Phase 3   EUCTR2015-000492-27-FR   France
ENV-101
   Endeavor Biomedicines, Inc.
      2024   Phase 2   NCT06422884   Argentina;Australia;Austria;Belgium;Canada;France;Germany;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Switzerland;United Kingdom;United States
Epigallocatechin-3-gallate
   Hal Chapman
      2017   Early Phase 1   NCT03928847   United States
Erivedge
   F. Hoffmann-La Roche Ltd.
      2014   -   EUCTR2014-000963-42-DE   Australia;Chile;France;Germany;Israel;Italy;Korea, Republic of;Mexico;New Zealand;Peru;Spain;United States
Esbriet
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2015   Phase 4   EUCTR2015-000640-42-IT   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim France
      2015   Phase 4   EUCTR2015-000640-42-FR   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim Pharma GmbH & Co.KG
      2015   Phase 4   EUCTR2015-000640-42-DE   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim bv
      2015   Phase 4   EUCTR2015-000640-42-NL   Canada;France;Germany;Italy;Netherlands;United States
   CIBER - Instituto Carlos III
      2018   Phase 4   EUCTR2016-003827-45-GB   Greece;Spain;United Kingdom
   CIBERES - Instituto Carlos III
      2018   Phase 4   EUCTR2016-003827-45-GR   Greece;Spain;United Kingdom
   F. HOFFMANN - LA ROCHE LTD.
      2016   Phase 2   EUCTR2015-005131-40-IT   Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
   F. Hoffmann-La Roche Ltd
      2017   Phase 2   EUCTR2015-005131-40-HU   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2017   Phase 2   EUCTR2015-005131-40-CZ   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-NL   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-GR   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-ES   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-DE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-BE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 4   EUCTR2015-003280-11-NL   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2016   Phase 4   EUCTR2015-003280-11-DK   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2016   Phase 4   EUCTR2015-003280-11-DE   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2014   Phase 2   EUCTR2013-001163-24-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-PL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
   Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
      2015   Phase 4   EUCTR2015-003280-11-ES   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
Esbriet - 267 MG - capsula rigida - USO orale - flacone (hdpe) 270 capsule
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 4   EUCTR2015-003280-11-IT   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
Esbriet 267 MG oral capsule
   Excalibur Pharmaceuticals, Inc.
      2022   Phase 1   NCT05428150   United States
Etanercept
   Wyeth is now a wholly owned subsidiary of Pfizer
      2003   Phase 2   NCT00063869   United States
Etoposide
   Fujimoto Daichi
      2021   -   JPRN-jRCTs051200109   -
   IKEDA Satoshi
      2019   Phase 2   JPRN-jRCTs031190119   -
EXCL-100, 600 MG oral tablet
   Excalibur Pharmaceuticals, Inc.
      2022   Phase 1   NCT05428150   United States
EZ-2053 5MG/KG
   Neovii Biotech
      2005   Phase 3   NCT00105183   Australia;Austria;Canada;United States
Factor xiia antagonist monoclonal antibody
   CSL Behring LLC
      2022   Phase 2   EUCTR2021-003162-12-PL   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003162-12-DK   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003162-12-DE   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003162-12-BE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003162-12-AT   Australia;Austria;Belgium;Canada;Czechia;Denmark;Germany;Italy;Poland;Spain;United Kingdom;United States
FDG PET scan
   University College, London
      2016   -   NCT02885961   -
FG-3019
   FIBROGEN
      2020   Phase 3   EUCTR2020-000697-22-IT   Belgium;Brazil;Bulgaria;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom
   FibroGen
      2011   Phase 2   NCT01262001   United States
      2003   Phase 1   NCT00074698   United States
   FibroGen, Inc.
      2021   Phase 3   EUCTR2020-000697-22-PL   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom
      2021   Phase 3   EUCTR2020-000697-22-IE   Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom
      2020   Phase 3   EUCTR2020-000697-22-NL   Argentina;Brazil;China;Colombia;Czech Republic;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000697-22-HU   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom
      2020   Phase 3   EUCTR2020-000697-22-FR   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom
      2020   Phase 3   EUCTR2020-000697-22-ES   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom
      2020   Phase 3   EUCTR2020-000697-22-DK   Argentina;Brazil;China;Colombia;Czech Republic;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000697-22-DE   Argentina;Brazil;China;Colombia;Czech Republic;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000697-22-CZ   Argentina;Brazil;China;Colombia;Czech Republic;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;United States
FG-3019 10MG/ML IN 10 ML vials
   FibroGen, Inc.
      2016   Phase 2   EUCTR2014-005658-20-BG   Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States
Fludarabine
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States
Fluimucil® 600 MG effervescent tablets
   InterMune International AG.
      2013   -   EUCTR2012-000564-14-SE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-IT   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   Phase 2   EUCTR2012-000564-14-GB   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-DK   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-DE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-BE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-AT   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
Formoterol fumarate dihydrate
   Hull and East Yorkshire Hospitals NHS Trust
      2014   -   EUCTR2013-004404-19-GB   United Kingdom
Fostair
   Hull University Teaching Hospitals NHS Trust
      2014   Phase 2   NCT02048644   United Kingdom
   Hull and East Yorkshire Hospitals NHS Trust
      2014   -   EUCTR2013-004404-19-GB   United Kingdom
Fxiia inhibitor monoclonal antibody
   CSL Behring Innovation GmbH
      2022   Phase 2   EUCTR2021-003162-12-IT   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Latvia;Lithuania;Norway;Poland;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States
   CSL Behring LLC
      2022   Phase 2   EUCTR2021-003162-12-PL   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003162-12-DK   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003162-12-DE   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003162-12-BE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-003162-12-AT   Australia;Austria;Belgium;Canada;Czechia;Denmark;Germany;Italy;Poland;Spain;United Kingdom;United States
G-CSF
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States
G321605
   Galapagos NV
      2019   Phase 2   EUCTR2017-004302-18-RO   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
      2019   Phase 2   EUCTR2017-004302-18-HR   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
      2019   Phase 2   EUCTR2017-004302-18-FI   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
      2018   Phase 2   EUCTR2017-004302-18-SK   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
      2018   Phase 2   EUCTR2017-004302-18-SE   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
      2018   Phase 2   EUCTR2017-004302-18-FR   Bulgaria;Croatia;Egypt;Finland;France;Lebanon;Oman;Romania;Slovakia;Sweden;Ukraine
      2018   Phase 2   EUCTR2017-004302-18-BG   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
G451990
   GALAPAGOS NV
      2018   Phase 3   EUCTR2018-001406-29-IT   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2016   Phase 2   EUCTR2015-004157-41-IT   Italy;United Kingdom
   Galapagos NV
      2019   Phase 3   EUCTR2018-001406-29-NL   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2019   Phase 3   EUCTR2018-001406-29-HU   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2019   Phase 3   EUCTR2018-001406-29-FR   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2019   Phase 3   EUCTR2018-001405-87-GR   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001405-87-GB   Australia;Belgium;Brazil;Chile;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001405-87-DE   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001405-87-CZ   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001405-87-BE   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001406-29-PL   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2018   Phase 3   EUCTR2018-001405-87-ES   Australia;Belgium;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001405-87-DK   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004157-41-GB   Ukraine;United Kingdom
Gallium68-DOTA-NOC
   AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
      2012   Phase 2   EUCTR2011-003687-78-IT   Italy
      2009   Phase 4   EUCTR2008-007168-40-IT   Italy
GB0139
   Galecto Biotech AB
      2020   Phase 2   EUCTR2018-002664-73-IE   Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2   NCT03832946   Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002664-73-PL   Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
GBT440
   Global Blood Therapeutics
      2016   Phase 2   NCT02989168   United Kingdom;United States
      2016   Phase 2   NCT02846324   United States
GBT440 300 MG capsule
   Global Blood Therapeutics Inc.
      2017   Phase 2   EUCTR2017-001276-27-GB   United Kingdom;United States
GBT440 300 MG tablet
   Global Blood Therapeutics Inc.
      2017   Phase 2   EUCTR2017-001276-27-GB   United Kingdom;United States
GC1008
   Genzyme, a Sanofi Company
      2005   Phase 1   NCT00125385   Belgium;United States
Gefapixant
   Afferent Pharmaceuticals, Inc.
      2015   Phase 2   NCT02502097   United States
      2015   Phase 2   NCT02477709   United States
Genetic analysis
   Imperial College London
      2017   -   NCT03211507   United Kingdom
GKT137831
   University of Alabama at Birmingham
      2020   Phase 2   NCT03865927   United States
GLPG1205
   Galapagos NV
      2019   Phase 2   EUCTR2017-004302-18-RO   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
      2019   Phase 2   EUCTR2017-004302-18-HR   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
      2019   Phase 2   EUCTR2017-004302-18-FI   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
      2018   Phase 2   NCT03725852   Bulgaria;Croatia;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
      2018   Phase 2   EUCTR2017-004302-18-SK   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
      2018   Phase 2   EUCTR2017-004302-18-SE   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
      2018   Phase 2   EUCTR2017-004302-18-FR   Bulgaria;Croatia;Egypt;Finland;France;Lebanon;Oman;Romania;Slovakia;Sweden;Ukraine
      2018   Phase 2   EUCTR2017-004302-18-BG   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine
GLPG1690
   GALAPAGOS NV
      2018   Phase 3   EUCTR2018-001406-29-IT   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2016   Phase 2   EUCTR2015-004157-41-IT   Italy;United Kingdom
   Galapagos NV
      2019   Phase 3   EUCTR2018-001406-29-NL   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2019   Phase 3   EUCTR2018-001406-29-HU   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2019   Phase 3   EUCTR2018-001406-29-FR   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2019   Phase 3   EUCTR2018-001405-87-GR   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001405-87-GB   Australia;Belgium;Brazil;Chile;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001405-87-DE   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001405-87-CZ   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001405-87-BE   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   NCT03733444   Argentina;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2018   Phase 3   NCT03711162   Australia;Belgium;Brazil;Chile;Czechia;Denmark;Germany;Greece;Japan;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001406-29-PL   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2018   Phase 3   EUCTR2018-001405-87-ES   Australia;Belgium;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001405-87-DK   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004157-41-GB   Ukraine;United Kingdom
   Galapagos NV(ICCC;PPDSNBL)
      2020   Phase 3   JPRN-jRCT2080225268   Asia except Japan;Europe;Japan;North America
   Kayamori Takefumi
      2021   Phase 3   JPRN-jRCT2031210008   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Germany;Greece;Japan;Peru;Spain;Taiwan;Turkey;USA;United Kingdom
GLPG1690 600 MG QD
   Galapagos NV
      2016   Phase 2   NCT02738801   Italy;Ukraine;United Kingdom
Granulocyte colony stimulating factor
   Shanghai Pulmonary Hospital
      2015   -   ChiCTR-OOC-15005862   China
GS-6624
   Gilead Sciences
      2010   Phase 1   NCT01362231   United States
   Gilead Sciences, Inc.
      2013   -   EUCTR2012-001571-36-PL   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2013   -   EUCTR2012-001571-36-IT   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-001571-36-GB   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2013   -   EUCTR2012-001571-36-ES   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2013   -   EUCTR2012-001571-36-DE   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-001571-36-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-001571-36-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;United States
GSK2126458
   GlaxoSmithKline
      2013   Phase 1   NCT01725139   United Kingdom
GSK26346763: ([18F]-FBA-A20fmdv2) IV infusion
   GlaxoSmithKline
      2015   Phase 1   NCT02612051   United Kingdom
GSK3008348
   GlaxoSmithKline
      2017   Phase 1   NCT03069989   United Kingdom
GSK3008348 nebuliser solution
   GlaxoSmithKline
      2015   Phase 1   NCT02612051   United Kingdom
GSK3915393
   GlaxoSmithKline
      2024   Phase 1   NCT06625489   United States
      2024   Phase 2   NCT06317285   Argentina;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
HEC 68498
   Sunshine Lake Pharma Co., Ltd.
      2018   Phase 1   NCT03502902   United States
HEC585
   Sunshine Lake Pharma Co., Ltd.
      2021   Phase 1   NCT05383131   China
      2021   Phase 2   NCT05060822   China
      2020   Phase 1   NCT04512170   China
      2017   Phase 1   NCT03092102   United States
High dose bibf 1120 twice daily
   Boehringer Ingelheim
      2007   Phase 2   NCT00514683   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom
High resolution computed tomography (hrct) scans OF THE chest
   Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      2024   -   NCT06521125   -
HRS-9813
   Guangdong Hengrui Pharmaceutical Co., Ltd
      2025   Phase 1   NCT06821464   China
HSK44459 dose 1
   Haisco Pharmaceutical Group Co., Ltd.
      2025   Phase 2   NCT06764862   -
HSK44459 dose 2
   Haisco Pharmaceutical Group Co., Ltd.
      2025   Phase 2   NCT06764862   -
HUL001
   HuniLife Biotechnology, Inc.
      2021   Phase 1   NCT04540770   Taiwan
Human umbilical cord mesenchymal stem cell injection
   Shanghai Life Science & Technology
      2022   Phase 1   NCT05468502   China
Humanized ANTI-alpha V beta 6 MAB
   BIOGEN IDEC RESEARCH LIMITED
      2018   Phase 2   EUCTR2017-003158-18-IT   Argentina;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
   Biogen Idec Research Limited
      2019   Phase 2   EUCTR2017-003158-18-PL   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2017-003158-18-DE   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-NL   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-GR   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-GB   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-ES   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-DK   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-CZ   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003158-18-BE   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
Hydroxyurea
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States
Hymecromone
   National Institute of Environmental Health Sciences (NIEHS)
      2025   Phase 2   NCT06325696   United States
Hyperoxia
   University of British Columbia
      2024   -   NCT03800017   Canada
Hyperpolarized 129 xenon GAS comparing idiopathic pulmonary fibrosis (IPF) treatment
   Duke University
      2020   Phase 2   NCT04071769   United States
Hyperpolarized 129 xenon GAS comparing progressive pulmonary fibrosis treatment
   Duke University
      2022   Phase 2   NCT05241275   United States
Hyperpolarized 129-xenon GAS
   Bastiaan Driehuys
      2015   Phase 1   NCT02478268   United States
Hyperpolarized XE129
   University of Kansas Medical Center
      2022   Phase 2   NCT04677426   -
   University of Virginia
      2025   Early Phase 1   NCT06853145   United States
HZN-825
   Amgen
      2021   Phase 2   NCT05032066   Argentina;Australia;Canada;Chile;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
   Horizon Therapeutics Ireland DAC
      2022   Phase 2   EUCTR2021-001253-32-NL   Argentina;Australia;Canada;Chile;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;United States
      2022   Phase 2   EUCTR2021-001253-32-GR   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001253-32-FR   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001253-32-ES   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
IDL-2965 oral capsule
   Indalo Therapeutics, Inc.
      2019   Phase 1   NCT03949530   United Kingdom
Ifetroban sodium
   Cumberland Pharmaceuticals
      2024   Phase 2   NCT05571059   United States
Iloprost
   Actelion
      2005   Phase 2   NCT00109681   United States
Imatinib
   Daniels, Craig E., M.D.
      2003   Phase 2/Phase 3   NCT00131274   -
Immukin
   InterMune
      2005   Phase 3   EUCTR2004-001261-17-IE   Ireland
      2005   Phase 3   EUCTR2004-000029-31-IE   Ireland
Inhaled carbon monoxide
   Brigham and Women's Hospital
      2011   Phase 2   NCT01214187   United States
Inhaled nitric oxide
   Geno LLC
      2011   Phase 2   NCT01265888   United States
Inhaled nitric oxide - 30 MCG/KG IBW/HR
   Bellerophon
      2015   Phase 1   NCT02267655   Belgium
Inhaled nitric oxide 5,10,15 MCG/KG IBW/HR
   Bellerophon
      2015   Phase 1   NCT02267655   Belgium
Inhaled nitric oxide 75 MCG/KG IBW/HR
   Bellerophon
      2015   Phase 1   NCT02267655   Belgium
Inhaled TD139
   Galecto Biotech AB
      2014   Phase 1/Phase 2   NCT02257177   United Kingdom
Inhaled treprostinil
   United Therapeutics
      2022   Phase 3   NCT05255991   Argentina;Australia;Belgium;Chile;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Peru;Spain;Taiwan
      2022   Phase 3   NCT04905693   Argentina;Australia;Belgium;Canada;Chile;Denmark;France;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Peru;Spain;Taiwan;United States
      2021   Phase 3   NCT04708782   Cameroon;Canada;Chile;United States
INO
   Bellerophon Pulse Technologies LLC
      2014   Phase 1;Phase 2   EUCTR2014-003423-21-BE   Belgium
Inomax 400PPM MOL/MOL inhalation GAS
   Bellerophon Pulse Technologies LLC
      2014   Phase 1;Phase 2   EUCTR2014-003423-21-BE   Belgium
INS018_055
   InSilico Medicine Hong Kong Limited
      2024   Phase 2   NCT05975983   United States
      2023   Phase 2   NCT05938920   China;United States
      2022   Phase 1   NCT05154240   New Zealand
Interferon alpha oral lozenge
   Texas Tech University Health Sciences Center
      2000   Phase 2   NCT01442779   United States
Interferon gamma-1B
   InterMune
      2005   Phase 3   EUCTR2004-001261-17-IE   Ireland
      2005   Phase 3   EUCTR2004-000029-31-IE   Ireland
      2003   Phase 3   NCT00076635   United States
      2003   Phase 3   NCT00075998   United States
Interferon-alpha lozenges
   Amarillo Biosciences, Inc.
      2008   Phase 2   NCT00690885   United States
Interferon-gamma 1B
   InterMune
      2002   Phase 2   NCT00052052   United States
      2002   Phase 3   NCT00052039   Italy
      2001   Phase 2   NCT00047658   United States
      2000   Phase 3   NCT00047645   United States
Intermediate dose bibf 1120 twice daily
   Boehringer Ingelheim
      2007   Phase 2   NCT00514683   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom
Intrapulmonary percussive ventilation
   University Hospital, Tours
      2022   -   NCT05366387   France
IV deployment OF csvf IN sterile normal saline IV solution
   Black Tie Medical, Inc.
      2020   Early Phase 1   NCT04326036   United States
IW001
   ImmuneWorks
      2010   Phase 1   NCT01199887   United States
Jaktinib hydrochloride tablets
   Suzhou Zelgen Biopharmaceuticals Co.,Ltd
      2020   Phase 2   NCT04312594   China
JIN-shui HUAN-xian granule
   Henan University of Traditional Chinese Medicine
      2025   -   NCT06914713   China
Knottin tracer
   Pliant Therapeutics, Inc.
      2019   Phase 2   NCT04072315   United States
L - antineoplastic and immunomodulating agents
   Boehringer Ingelheim
      2017   -   NCT03281200   Spain
L01 - antineoplastic agents
   Boehringer Ingelheim
      2017   -   NCT03281200   Spain
L01X - other antineoplastic agents
   Boehringer Ingelheim
      2017   -   NCT03281200   Spain
L01XE - protein kinase inhibitors
   Boehringer Ingelheim
      2017   -   NCT03281200   Spain
L01xe31 - nintedanib
   Boehringer Ingelheim
      2017   -   NCT03281200   Spain
Laboratory assessments
   Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      2024   -   NCT06521125   -
Lanreotide acetate
   AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
      2012   Phase 2   EUCTR2011-003687-78-IT   Italy
Lansoprazole
   Huang Jinhong
      2021   Phase 1   JPRN-jRCT2071210016   -
   Norfolk and Norwich University Hospitals NHS Foundation Trust
      2021   Phase 3   NCT04965298   United Kingdom
      2020   Phase 3   EUCTR2020-000041-14-GB   United Kingdom
Lebrikizumab
   Chugai Pharmaceutical Co., Ltd.
      2014   Phase 2   JPRN-jRCT2080222657   -
   F. Hoffmann-La Roche Ltd
      2014   Phase 2   EUCTR2013-001163-24-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-PL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-ES   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
   Hoffmann-La Roche
      2013   Phase 2   NCT01872689   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
Leramistat
   Modern Biosciences Ltd
      2023   Phase 2   NCT05951296   France;Germany;Greece;Hungary;Israel;Italy;Spain;United Kingdom;United States
Letairis
   Gilead Sciences Incorporated
      2009   -   EUCTR2009-011169-98-IT   Austria;Czech Republic;Germany;Italy;United Kingdom
   Gilead Sciences, Inc
      2009   -   EUCTR2009-011169-98-GB   Austria;Czech Republic;Germany;Italy;United Kingdom
      2009   -   EUCTR2009-011169-98-DE   Austria;Czech Republic;Germany;Italy;United Kingdom
      2009   -   EUCTR2009-011169-98-AT   Austria;Czech Republic;Germany;Italy;United Kingdom
   Gilead Sciences, Inc.
      2011   -   EUCTR2009-011169-98-CZ   Austria;Czech Republic;Germany;Italy;United Kingdom
Letairis 10 MG
   Gilead Sciences Incorporated
      2010   -   EUCTR2008-004405-34-CZ   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-004405-34-NL   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-GB   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-004405-34-FR   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-ES   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-BE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-AT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      -   -   EUCTR2008-004405-34-DE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
Letairis 5 MG
   Gilead Sciences Incorporated
      2010   -   EUCTR2008-004405-34-CZ   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-004405-34-NL   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-GB   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-004405-34-FR   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-ES   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-BE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-004405-34-AT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      -   -   EUCTR2008-004405-34-DE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
Letermovir
   Fernanda P Silveira, MD, MS
      2021   Phase 2   NCT05041426   United States
Losartan
   University of South Florida
      2009   -   NCT00879879   United States
LOW dose bibf 1120 twice daily
   Boehringer Ingelheim
      2007   Phase 2   NCT00514683   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom
LOW dose BIBF1120 once daily
   Boehringer Ingelheim
      2007   Phase 2   NCT00514683   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom
LPA1
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2020   Phase 2   EUCTR2019-003992-21-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2020   Phase 2   EUCTR2019-003992-21-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States
LTI-03
   Lung Therapeutics, Inc
      2020   Phase 1   NCT04233814   United Kingdom
   Rein Therapeutics
      2025   Phase 2   NCT06968845   United States
      2023   Phase 1   NCT05954988   Germany;United Kingdom;United States
LTP001
   Novartis Pharma AG
      2023   Phase 2   EUCTR2021-005066-17-PL   Argentina;Australia;Czechia;Germany;Netherlands;Poland;United Kingdom;United States
      2023   Phase 2   EUCTR2021-005066-17-NL   Argentina;Australia;Czechia;Germany;Netherlands;Poland;United Kingdom;United States
      2023   Phase 2   EUCTR2021-005066-17-DE   Argentina;Australia;Czechia;Germany;Netherlands;Poland;United Kingdom;United States
   Novartis Pharmaceuticals
      2022   Phase 2   NCT05497284   Argentina;Australia;Czechia;Germany;Netherlands;Poland;United States
Lung spheroid stem cells 100 million
   University of North Carolina, Chapel Hill
      2020   Phase 1   NCT04262167   United States
Lung spheroid stem cells 200 million
   University of North Carolina, Chapel Hill
      2020   Phase 1   NCT04262167   United States
Lung stem cells
   Shanghai East Hospital
      2017   Phase 1/Phase 2   NCT02745184   China
LYT-100
   PureTech LYT 100, Inc.
      2022   Phase 2   EUCTR2021-006820-41-RO   Argentina;Chile;Colombia;Georgia;Greece;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Serbia;South Africa;Thailand;United States
      2022   Phase 2   EUCTR2021-006820-41-GR   Argentina;Chile;Colombia;Georgia;Greece;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;South Africa;Thailand;United States
Macitentan
   ACTELION Pharmaceuticals Ltd.
      2011   Phase 2   EUCTR2010-024211-13-SI   Australia;Canada;Germany;Israel;Slovenia;South Africa;Spain;Sweden;Turkey;United States
      2011   Phase 2   EUCTR2010-024211-13-SE   Australia;Canada;Germany;Israel;Slovenia;South Africa;Spain;Sweden;Turkey;United States
      2011   Phase 2   EUCTR2010-024211-13-ES   Australia;Canada;Germany;Israel;Slovenia;South Africa;Spain;Sweden;Turkey;United States
      2011   -   EUCTR2010-024211-13-DE   Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States
   Actelion
      2011   Phase 2   NCT01346930   -
      2009   Phase 2   NCT00903331   Australia;Canada;France;Germany;Israel;Italy;Slovenia;South Africa;Spain;Sweden;Turkey;United States
   Actelion Pharamceuticals Ltd
      2010   -   EUCTR2008-006054-17-IT   France;Germany;Italy;Slovenia;Spain;Sweden
   Actelion Pharmaceuticals Ltd.
      2009   -   EUCTR2008-006054-17-SI   France;Germany;Italy;Slovenia;Spain;Sweden
      2009   -   EUCTR2008-006054-17-SE   France;Germany;Italy;Slovenia;Spain;Sweden
      2009   Phase 2   EUCTR2008-006054-17-FR   France;Germany;Italy;Slovenia;Spain;Sweden
      2009   Phase 2   EUCTR2008-006054-17-ES   France;Germany;Italy;Slovenia;Spain;Sweden
      -   -   EUCTR2008-006054-17-DE   France;Germany;Italy;Slovenia;Spain;Sweden
Medical AIR
   Dr. Denis O'Donnell
      2022   Early Phase 1   NCT05052229   Canada
   George Papanicolaou Hospital
      2018   -   NCT03688334   Greece
   Schön Klinik Berchtesgadener Land
      2016   -   NCT03050255   Germany
Mesna
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2015   Phase 3   EUCTR2015-000492-27-FR   France
Methylprednisolone
   Assiut University
      2023   -   NCT05842681   Egypt
   Nanjing Drum Tower Hospital, The Affiliated Nanjing University Medical School
      2022   -   ChiCTR2200058688   China
Methylprednisolone hemisuccinate
   Groupe Hospitalier Paris Saint-Joseph
      2022   Phase 2   EUCTR2022-002464-75-FR   France
Methylprednisolone sodium hemisuccinate
   Groupe Hospitalier Paris Saint-Joseph
      2022   Phase 2   EUCTR2022-002464-75-FR   France
Methylprednisone/prednisone
   Fondation Hôpital Saint-Joseph
      2023   Phase 3   NCT05674994   France
MG-S-2525
   Metagone Biotech Inc.
      2019   Phase 1   NCT03650075   Taiwan
Minocycline
   University of California, Los Angeles
      2006   Phase 3   NCT00203697   United States
Mirtazapine
   China-Japan Friendship Hospital
      2024   -   ChiCTR2400092007   China
Montelukast
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada
   Shanghai Pulmonary Hospital
      2015   -   ChiCTR-OOC-15005841   -
Morphine hydrochloride
   Medical University of Gdansk
      2020   Phase 3   NCT04497831   -
Morphine sulfate
   Royal Brompton & Harefield NHS Foundation Trust
      2020   Phase 3   NCT04429516   United Kingdom
   Royal Brompton and Harefield NHS Foundation Trust
      2020   Phase 3   EUCTR2019-003571-19-GB   United Kingdom
Moxifloxacin
   Respiratory Department, Peking Union Medical College Hospital
      2011   -   ChiCTR-TRC-12002372   China
MTX-463
   Mediar Therapeutics
      2025   Phase 2   NCT06967805   United States
N-acetyl cysteine
   University of Colorado, Denver
      2022   Phase 1/Phase 2   NCT03720483   United States
   Weill Medical College of Cornell University
      2020   Phase 3   NCT04300920   United States
N-acetylcysteine
   Hoffmann-La Roche
      2013   Phase 2   NCT02707640   Austria;Belgium;Denmark;France;Germany;Italy;Sweden;United Kingdom
   InterMune International AG.
      2013   -   EUCTR2012-000564-14-SE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-IT   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   Phase 2   EUCTR2012-000564-14-GB   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-DK   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-DE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-BE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-AT   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
   Saitama Red Cross Hospital
      2013   -   JPRN-UMIN000016706   Japan
   Zambon SpA
      2000   Phase 3   NCT00639496   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
NAC
   Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.
      2015   -   JPRN-UMIN000015508   Japan
   InterMune International AG.
      2013   -   EUCTR2012-000564-14-SE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-IT   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   Phase 2   EUCTR2012-000564-14-GB   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-DK   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-DE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-BE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
      2013   -   EUCTR2012-000564-14-AT   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom
   Shanghai Pulmonary Hospital, Tongji University School of Medicine
      2020   -   ChiCTR2000031386   China
NAL ER
   Trevi Therapeutics
      2019   Phase 2   NCT04030026   United Kingdom
Nalbuphine ER 108 MG
   Trevi Therapeutics
      2024   Phase 2   NCT05964335   Australia;Canada;Chile;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom
Nalbuphine ER 27 MG
   Trevi Therapeutics
      2024   Phase 2   NCT05964335   Australia;Canada;Chile;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom
Nalbuphine ER 54 MG
   Trevi Therapeutics
      2024   Phase 2   NCT05964335   Australia;Canada;Chile;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom
Nalbuphine extended-realease (ER) tablets
   Trevi Therapeutics, Inc.
      2019   Phase 2   EUCTR2018-004744-31-GB   United Kingdom
Nalbuphine extended-release (ER) tablets
   Trevi Therapeutics, Inc.
      2019   Phase 2   EUCTR2018-004744-31-GB   United Kingdom
Nalbuphine hydrochloride
   Trevi Therapeutics, Inc.
      2019   Phase 2   EUCTR2018-004744-31-GB   United Kingdom
Nandrolone decanoate
   University of Sao Paulo
      2014   Phase 1/Phase 2   NCT02055456   Brazil
ND-L02-S0201 FOR injection
   Nitto Denko Corporation
      2018   Phase 2   EUCTR2017-004919-39-DE   Germany;Japan;United Kingdom;United States
Nebivolol
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04888728   Korea, Republic of
Nicotinamide riboside
   Cedars-Sinai Medical Center
      2025   Phase 2   NCT06567717   United States
Nintedanib
   BOEHRINGER ING.
      2012   Phase 3   EUCTR2011-002766-21-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2016   Phase 3   EUCTR2015-002619-14-IT   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
      2015   Phase 4   EUCTR2015-000640-42-IT   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim
      2024   -   NCT06485635   France
      2023   -   NCT05870956   United States
      2023   -   NCT05779007   United States
      2021   -   NCT04739150   Belgium
      2021   -   NCT04525547   Korea, Republic of
      2019   -   NCT03958071   United States
      2019   -   NCT03710824   Greece
      2018   Phase 4   NCT03717012   United States
      2017   -   NCT03047031   India
      2016   Phase 3   NCT02802345   Australia;Belgium;Canada;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
      2016   Phase 4   NCT02788474   Australia;Belgium;Czech Republic;Czechia;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 4   NCT02606877   United Kingdom
      2015   -   NCT02607722   Japan
      2015   Phase 4   NCT02579603   Canada;France;Germany;Italy;Netherlands;United States
      2014   -   NCT02230982   Brazil
      2014   -   NCT02171156   United States
      2013   Phase 3   NCT01979952   Canada;Turkey;United States
      2012   Phase 3   EUCTR2011-002766-21-FI   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2011   Phase 2   NCT01417156   Japan
   Boehringer Ingelheim Hellas
      2012   Phase 3   EUCTR2011-002766-21-GR   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Boehringer Ingelheim España S.A
      2012   Phase 3   EUCTR2011-002766-21-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Boehringer Ingelheim España, S.A.
      2016   Phase 4   EUCTR2015-003148-38-ES   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002619-14-ES   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim Finland Ky
      2016   Phase 4   EUCTR2015-003148-38-FI   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
   Boehringer Ingelheim France
      2017   Phase 3   EUCTR2015-002619-14-FR   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-003148-38-FR   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2015   Phase 4   EUCTR2015-000640-42-FR   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim Limited
      2016   Phase 4   EUCTR2015-003148-38-GB   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002619-14-GB   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
      2013   Phase 3   EUCTR2011-002766-21-IE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2012   Phase 3   EUCTR2011-002766-21-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2016   Phase 4   EUCTR2015-003148-38-DE   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002619-14-DE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-002766-21-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co.KG
      2015   Phase 4   EUCTR2015-000640-42-DE   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim RCV GmBH & Co KG
      2010   Phase 2   EUCTR2009-013788-21-HU   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom
   Boehringer Ingelheim RCV GmbH & Co KG
      2016   Phase 4   EUCTR2015-003148-38-PL   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-003148-38-HU   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-003148-38-CZ   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2012   Phase 3   EUCTR2011-002766-21-CZ   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2010   Phase 2   EUCTR2009-013788-21-CZ   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Russian Federation;Spain;United Kingdom
   Boehringer Ingelheim bv
      2015   Phase 4   EUCTR2015-000640-42-NL   Canada;France;Germany;Italy;Netherlands;United States
   Central Japan Lung Study Grou
      2017   Phase 4   JPRN-UMIN000026376   Japan
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04888715   Korea, Republic of
   Endeavor Biomedicines, Inc.
      2023   Phase 1   NCT05817240   Australia
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 4   EUCTR2015-003280-11-IT   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
   F. Hoffmann-La Roche Ltd
      2016   Phase 4   EUCTR2015-003280-11-NL   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2016   Phase 4   EUCTR2015-003280-11-DK   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2016   Phase 4   EUCTR2015-003280-11-DE   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
   GlaxoSmithKline
      2024   Phase 1   NCT06625489   United States
   Hirosaki University Graduate School of Medicine
      2016   -   JPRN-UMIN000021591   Japan
   Hoffmann-La Roche
      2016   Phase 4   NCT02598193   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
   Hospices Civils de Lyon
      2020   Phase 3   EUCTR2019-004326-19-FR   France
   IKEDA Satoshi
      2019   Phase 2   JPRN-jRCTs031190119   -
   Japanese Red Cross Medical Canter
      2019   -   JPRN-UMIN000039027   Japan
   Kanagawa Cardiovascular and Respiratory Center
      2016   -   JPRN-UMIN000020722   Japan
      2015   Phase 2   JPRN-UMIN000019436   Japan
   National Hospital Organization Ibarakihigashi National Hospital The center of Chest Diseases and Severe Motor&Intellectual Disabilities
      2016   -   JPRN-UMIN000020682   Japan
   Okada Morihito
      2023   Phase 2   JPRN-jRCT1061220064   -
   Okamoto Isamu
      2017   Phase 3   JPRN-jRCTs071180049   -
   Research Institute for Diseases of the Chest, Kyushu University
      2017   Phase 3   JPRN-UMIN000026799   Japan
   Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
      2015   Phase 4   EUCTR2015-003280-11-ES   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 3   EUCTR2015-002619-14-BE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 4   EUCTR2015-003148-38-BE   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
   SCS Boehringer Ingelheim Ingelheim Comm.V
      2012   Phase 3   EUCTR2011-002766-21-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Sunshine Lake Pharma Co., Ltd.
      2021   Phase 1   NCT05383131   China
   Temple University
      2019   Phase 2   NCT03562416   United States
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
      2012   Phase 3   EUCTR2011-002766-21-PT   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
NIP292 tablet
   The National Institutes of Pharmaceutical R&D Co. Ltd, China
      2019   Phase 1   NCT04720443   United States
NIP292 tablets
   The National Institutes of Pharmaceutical R&D Co. Ltd, China
      2019   Phase 1   NCT04720443   United States
Nitrate-rich beetroot juice (70ML with approx. 400 MG nitrate) twice A DAY FOR 3 days
   University Hospital Southampton NHS Foundation Trust
      2024   -   NCT06488638   -
Nitric oxide
   Bellerophon Pulse Technologies LLC
      2014   Phase 1;Phase 2   EUCTR2014-003423-21-BE   Belgium
   Dr. Denis O'Donnell
      2022   Early Phase 1   NCT05052229   Canada
Nivolumab
   Kobe city medical center general hospital
      2016   -   JPRN-UMIN000022037   Japan
None YET
   Boehringer Ingelheim AB
      2022   Phase 3   EUCTR2022-001091-34-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Boehringer Ingelheim RCV GmbH & Co KG
      2023   Phase 3   EUCTR2022-001091-34-SI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001091-34-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Czechia;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Boehringer Ingelheim SComm
      2023   Phase 3   EUCTR2022-001091-34-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
   Boehringer-Ingelheim B.V.
      2022   Phase 3   EUCTR2022-001091-34-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Saudi Arabia;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Türkiye;United Kingdom;United States
Octreotide
   Institut National de la Santé Et de la Recherche Médicale, France
      2006   Phase 1/Phase 2   NCT00463983   France
Ofev
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2015   Phase 4   EUCTR2015-000640-42-IT   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim
      2021   -   NCT04614441   Taiwan
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 4   EUCTR2015-003280-11-IT   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
   F. Hoffmann-La Roche Ltd
      2016   Phase 4   EUCTR2015-003280-11-NL   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2016   Phase 4   EUCTR2015-003280-11-DK   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2016   Phase 4   EUCTR2015-003280-11-DE   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
   Okada Morihito
      2023   Phase 2   JPRN-jRCT1061220064   -
   Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
      2015   Phase 4   EUCTR2015-003280-11-ES   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
Ofev 100 MG capsule
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2016   Phase 3   EUCTR2015-002619-14-IT   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim España, S.A.
      2016   Phase 4   EUCTR2015-003148-38-ES   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002619-14-ES   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim Finland Ky
      2016   Phase 4   EUCTR2015-003148-38-FI   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
   Boehringer Ingelheim France
      2017   Phase 3   EUCTR2015-002619-14-FR   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-003148-38-FR   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2015   Phase 4   EUCTR2015-000640-42-FR   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim Limited
      2016   Phase 4   EUCTR2015-003148-38-GB   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002619-14-GB   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2016   Phase 4   EUCTR2015-003148-38-DE   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002619-14-DE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co.KG
      2015   Phase 4   EUCTR2015-000640-42-DE   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim RCV GmbH & Co KG
      2016   Phase 4   EUCTR2015-003148-38-PL   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-003148-38-HU   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-003148-38-CZ   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
   Boehringer Ingelheim bv
      2015   Phase 4   EUCTR2015-000640-42-NL   Canada;France;Germany;Italy;Netherlands;United States
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 3   EUCTR2015-002619-14-BE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 4   EUCTR2015-003148-38-BE   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
Ofev 150 MG capsule
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2016   Phase 3   EUCTR2015-002619-14-IT   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim España, S.A.
      2016   Phase 4   EUCTR2015-003148-38-ES   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002619-14-ES   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim Finland Ky
      2016   Phase 4   EUCTR2015-003148-38-FI   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
   Boehringer Ingelheim France
      2017   Phase 3   EUCTR2015-002619-14-FR   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-003148-38-FR   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2015   Phase 4   EUCTR2015-000640-42-FR   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim Limited
      2016   Phase 4   EUCTR2015-003148-38-GB   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002619-14-GB   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2016   Phase 4   EUCTR2015-003148-38-DE   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002619-14-DE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co.KG
      2015   Phase 4   EUCTR2015-000640-42-DE   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim RCV GmbH & Co KG
      2016   Phase 4   EUCTR2015-003148-38-PL   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-003148-38-HU   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2016   Phase 4   EUCTR2015-003148-38-CZ   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
   Boehringer Ingelheim bv
      2015   Phase 4   EUCTR2015-000640-42-NL   Canada;France;Germany;Italy;Netherlands;United States
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 3   EUCTR2015-002619-14-BE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 4   EUCTR2015-003148-38-BE   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
Omeprazole
   Chinese PLA General Hospital
      2023   Phase 1   ChiCTR2300071134   China
   Newcastle Upon Tyne Hospitals NHS Foundation Trust
      2013   Phase 2   EUCTR2013-003301-26-GB   United Kingdom
   Newcastle-upon-Tyne Hospitals NHS Trust
      2014   Phase 2   NCT02085018   United Kingdom
ORIN1001
   Orinove, Inc.
      2021   Phase 1   NCT04643769   United States
Orvepitant
   NeRRe Therapeutics Ltd
      2022   Phase 2   EUCTR2021-006278-22-NL   Netherlands;United Kingdom;United States
Orvepitant maleate
   Nerre Therapeutics Ltd.
      2022   Phase 2   NCT05185089   Netherlands;United Kingdom;United States
Oxygen
   Brigham and Women's Hospital
      2011   Phase 2   NCT01214187   United States
   Department of Respiratory Medicine and Allergology, Kinki University School of Medicine
      2011   -   JPRN-UMIN000005098   Japan
   George Papanicolaou Hospital
      2018   -   NCT03688334   Greece
   Parc de Salut Mar
      2019   -   NCT04564664   Spain
   Schön Klinik Berchtesgadener Land
      2016   -   NCT03050255   Germany
   Tosei General Hospital
      2009   -   JPRN-UMIN000025256   Japan
PA101
   Patara Pharma
      2015   Phase 2   NCT02412020   Netherlands;United Kingdom
      2015   -   EUCTR2014-004025-40-NL   Netherlands;United Kingdom
      2014   Phase 2   EUCTR2014-004025-40-GB   Netherlands;United Kingdom
Paclitaxel
   Hirosaki University Graduate School of Medicine
      2016   -   JPRN-UMIN000021591   Japan
   IP lung cancer study group
      2012   -   JPRN-UMIN000018322   Japan
      2012   -   JPRN-UMIN000018248   Japan
   Katakami Nobuyuki
      2013   Phase 2   JPRN-jRCTs061180046   -
      2013   Phase 2   JPRN-jRCTs051180149   -
   Lung Oncology Group in Kyushu, Japan (LOGIK)
      2007   -   JPRN-UMIN000015929   Japan
   Okamoto Isamu
      2017   Phase 3   JPRN-jRCTs071180049   -
   Research Institute for Diseases of the Chest, Kyushu University
      2017   Phase 3   JPRN-UMIN000026799   Japan
Pamrevlumab
   Ewa Carrier
      2022   Phase 3   JPRN-jRCT2051210169   Argentina;Australia;Chile;Hong Kong;Japan;Russia;South Korea;Taiwan;United States;the People's Republic of China
   FIBROGEN
      2020   Phase 3   EUCTR2020-000697-22-IT   Belgium;Brazil;Bulgaria;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom
   FibroGen
      2020   Phase 3   NCT04419558   Argentina;Brazil;China;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;United States
      2019   Phase 3   NCT03955146   Argentina;Australia;Chile;China;Czechia;France;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lebanon;Netherlands;Peru;Russian Federation;Spain;Taiwan;United States
      2013   Phase 2   NCT01890265   Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States
   FibroGen, Inc.
      2021   Phase 3   EUCTR2020-000697-22-PL   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom
      2021   Phase 3   EUCTR2020-000697-22-IE   Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom
      2020   Phase 3   EUCTR2020-000697-22-NL   Argentina;Brazil;China;Colombia;Czech Republic;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000697-22-HU   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom
      2020   Phase 3   EUCTR2020-000697-22-FR   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom
      2020   Phase 3   EUCTR2020-000697-22-ES   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom
      2020   Phase 3   EUCTR2020-000697-22-DK   Argentina;Brazil;China;Colombia;Czech Republic;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000697-22-DE   Argentina;Brazil;China;Colombia;Czech Republic;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000697-22-CZ   Argentina;Brazil;China;Colombia;Czech Republic;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;United States
      2016   Phase 2   EUCTR2014-005658-20-BG   Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States
Paroxetine
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04888728   Korea, Republic of
PBI4050
   Liminal BioSciences Ltd.
      2015   Phase 2   NCT02538536   Canada
PD00377 NA-salt
   Vicore Pharma AB
      2018   Phase 2   EUCTR2017-004923-63-GB   Bulgaria;Poland;Serbia;United Kingdom
PET imaging
   Massachusetts General Hospital
      2018   Phase 1   NCT03535545   United States
PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
   University of Alabama at Birmingham
      2020   Phase 1   NCT04362644   United States
PIPE-791
   Contineum Therapeutics
      2024   Phase 1   NCT06683612   United Kingdom
PIR, S-7701
   INTERMUNE
      2006   -   EUCTR2006-000252-41-IT   Italy;United Kingdom
   InterMune, Inc.
      2008   Phase 3   EUCTR2007-007800-13-IE   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-007800-13-GB   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Poland;Spain;United Kingdom;United States
      2008   -   EUCTR2007-007800-13-FR   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-007800-13-ES   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-007800-13-DE   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom
      2008   -   EUCTR2007-007800-13-BE   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom
      2006   Phase 3   EUCTR2006-000252-41-GB   Italy;United Kingdom
      2006   Phase 3   EUCTR2006-000138-11-ES   Belgium;Czech Republic;Germany;Ireland;Spain
      2006   -   EUCTR2006-000138-11-DE   Belgium;Czech Republic;Germany;Ireland;Spain
      2006   -   EUCTR2006-000138-11-CZ   Belgium;Czech Republic;Germany;Ireland;Spain
      2006   -   EUCTR2006-000138-11-BE   Belgium;Czech Republic;Germany;Ireland;Spain
Pirfenidone
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2015   Phase 4   EUCTR2015-000640-42-IT   Canada;France;Germany;Italy;Netherlands;United States
   Beijing Kawin Technology Share-Holding Co., Ltd.
      2012   Phase 2   NCT01504334   China
   Boehringer Ingelheim
      2025   Phase 2   NCT06241560   Georgia
      2024   -   NCT06485635   France
      2023   -   NCT05779007   United States
      2019   -   NCT03958071   United States
      2017   -   NCT03047031   India
      2016   Phase 4   NCT02606877   United Kingdom
      2015   Phase 4   NCT02579603   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim France
      2015   Phase 4   EUCTR2015-000640-42-FR   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim Pharma GmbH & Co.KG
      2015   Phase 4   EUCTR2015-000640-42-DE   Canada;France;Germany;Italy;Netherlands;United States
   Boehringer Ingelheim bv
      2015   Phase 4   EUCTR2015-000640-42-NL   Canada;France;Germany;Italy;Netherlands;United States
   Bristol-Myers Squibb
      2019   Phase 1   NCT03981094   United States
   CIBER - Instituto Carlos III
      2018   Phase 4   EUCTR2016-003827-45-GB   Greece;Spain;United Kingdom
   CIBERES - Instituto Carlos III
      2018   Phase 4   EUCTR2016-003827-45-GR   Greece;Spain;United Kingdom
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04888715   Korea, Republic of
   Department of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine
      2012   -   JPRN-UMIN000008541   Japan
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 4   EUCTR2015-003280-11-IT   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
   F. Hoffmann-La Roche Ltd
      2017   Phase 2   EUCTR2015-005131-40-HU   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2017   Phase 2   EUCTR2015-005131-40-CZ   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-NL   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-GR   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-ES   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-DE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-BE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 4   EUCTR2015-003280-11-NL   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2016   Phase 4   EUCTR2015-003280-11-DK   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2016   Phase 4   EUCTR2015-003280-11-DE   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2014   Phase 2   EUCTR2013-001163-24-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-PL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
   Genentech, Inc.
      2014   -   NCT02141087   -
      2011   Phase 3   NCT01366209   United States
      2008   Phase 3   NCT00662038   United States
      2006   Phase 3   NCT00287729   United States
      2006   Phase 3   NCT00287716   United States
      2003   Phase 2   NCT00080223   United States
   Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.
      2015   -   JPRN-UMIN000015508   Japan
   Hoffmann-La Roche
      2017   Phase 3   NCT03208933   Russian Federation
      2017   -   NCT03115619   Greece
      2016   Phase 2   NCT02951429   Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 1   NCT02648048   Germany;United States
      2016   Phase 4   NCT02598193   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2014   -   NCT02622477   Germany
      2013   Phase 2   NCT02707640   Austria;Belgium;Denmark;France;Germany;Italy;Sweden;United Kingdom
      2013   Phase 2   NCT01872689   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2012   -   NCT02699879   Austria;Denmark;Finland;France;Germany;Ireland;Italy;Norway;Sweden;United Kingdom
   Hospices Civils de Lyon
      2020   Phase 3   EUCTR2019-004326-19-FR   France
   INTERMUNE
      2008   -   EUCTR2007-007800-13-IT   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom
   InterMune, Inc.
      2008   Phase 3   EUCTR2007-007800-13-IE   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-007800-13-GB   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Poland;Spain;United Kingdom;United States
      2008   -   EUCTR2007-007800-13-FR   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-007800-13-ES   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-007800-13-DE   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom
      2008   -   EUCTR2007-007800-13-BE   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom
      2006   Phase 3   EUCTR2006-000252-41-GB   Italy;United Kingdom
      2006   Phase 3   EUCTR2006-000138-11-ES   Belgium;Czech Republic;Germany;Ireland;Spain
      2006   -   EUCTR2006-000138-11-DE   Belgium;Czech Republic;Germany;Ireland;Spain
      2006   -   EUCTR2006-000138-11-CZ   Belgium;Czech Republic;Germany;Ireland;Spain
      2006   -   EUCTR2006-000138-11-BE   Belgium;Czech Republic;Germany;Ireland;Spain
   Japanese Red Cross Medical Canter
      2019   -   JPRN-UMIN000039027   Japan
   Kanagawa Cardiovascular and Respiratory Center
      2015   Phase 2   JPRN-UMIN000019436   Japan
   National Hospital Organization Ibarakihigashi National Hospital
      2015   -   JPRN-UMIN000016826   Japan
   National Hospital Organization Ibarakihigashi National Hospital The center of Chest Diseases and Severe Motor&Intellectual Disabilities
      2016   -   JPRN-UMIN000020682   Japan
   North East Japan Study Group
      2017   Phase 3   JPRN-UMIN000029411   Japan
   PureTech
      2022   Phase 2   NCT05321420   Argentina;Chile;Colombia;Georgia;Greece;India;Korea, Republic of;Malaysia;Mexico;Philippines;Romania;South Africa;Thailand;United States
   Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
      2015   Phase 4   EUCTR2015-003280-11-ES   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
   Saitama Medical University
      2009   -   JPRN-UMIN000005793   Japan
   Shanghai Pulmonary Hospital, Shanghai, China
      2011   Phase 2   NCT02136992   -
   Sunshine Lake Pharma Co., Ltd.
      2021   Phase 1   NCT05383131   China
      2021   Phase 2   NCT05060822   China
   Tianjin Medical University General Hospital
      2020   Phase 4   ChiCTR2000037602   China
   West Japan Oncology Group
      2012   Phase 2   JPRN-UMIN000007774   Japan
Pirfenidone and nintedanib
   Hospices Civils de Lyon
      2020   Phase 4   NCT03939520   France
Pirfenidone modified-release tablets
   Overseas Pharmaceuticals, Ltd.
      2024   Phase 1   NCT06588517   China
      2024   Phase 1   NCT06569381   China
      2023   Phase 1   NCT06589921   China
Pirfenidone or nintedanib
   Hospices Civils de Lyon
      2020   Phase 4   NCT03939520   France
   Kayamori Takefumi
      2021   Phase 3   JPRN-jRCT2031210008   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Germany;Greece;Japan;Peru;Spain;Taiwan;Turkey;USA;United Kingdom
Pirfenidone solution FOR inhalation
   Avalyn Pharma, Inc.
      2021   Phase 2   EUCTR2020-005103-39-PL   Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom
      2021   Phase 2   EUCTR2020-005103-39-NL   Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom
      2021   Phase 2   EUCTR2020-005103-39-CZ   Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom
Pirfenidone tablets
   Center for Clinical Pharmacology, the Third Xiangya Hospital of Central South University
      2022   Phase 1   ChiCTR2200064910   China
   Overseas Pharmaceuticals, Ltd.
      2024   Phase 1   NCT06588517   China
      2023   Phase 1   NCT06589921   China
Pirfenidone, deuterated
   PureTech LYT 100, Inc.
      2022   Phase 2   EUCTR2021-006820-41-RO   Argentina;Chile;Colombia;Georgia;Greece;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Serbia;South Africa;Thailand;United States
      2022   Phase 2   EUCTR2021-006820-41-GR   Argentina;Chile;Colombia;Georgia;Greece;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;South Africa;Thailand;United States
Pirfenidoneone
   Boehringer Ingelheim
      2011   Phase 2   NCT01417156   Japan
PLN-74809
   Pliant Therapeutics, Inc.
      2023   Phase 2   NCT06097260   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czechia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
      2022   Phase 2   NCT05621252   United States
      2020   Phase 2   NCT04396756   Australia;Belgium;Canada;Italy;Netherlands;New Zealand;United States
      2019   Phase 2   NCT04072315   United States
PLN-74809-000
   Pliant Therapeutics Inc.
      2020   Phase 2   EUCTR2019-002709-23-IT   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;New Zealand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002709-23-GB   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;New Zealand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002709-23-DE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;United Kingdom;United States
PLN-74809-020
   Pliant Therapeutics Inc.
      2021   Phase 2   EUCTR2019-002709-23-NL   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002709-23-DE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;United Kingdom;United States
PMG1015
   Pulmongene Ltd.
      2023   Phase 1   NCT05895565   China
PMG1015 dose 1
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia
PMG1015 dose 2
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia
PMG1015 dose 3
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia
PMG1015 dose 4
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia
PMG1015 dose 5
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia
PMG1015 dose 6
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia
PMG1015 dose 7
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia
Pomalidomide (CC-4047
   Stanford University
      2010   Phase 2   NCT01135199   United States
Prednisolone
   Takeshi Masuda
      2023   Phase 2   JPRN-jRCT1061220085   -
   University of Nottingham
      2011   -   EUCTR2010-023828-24-GB   United Kingdom
Prednisone
   Groupe Hospitalier Paris Saint-Joseph
      2022   Phase 2   EUCTR2022-002464-75-FR   France
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada
Prednisonum micronisatum
   Groupe Hospitalier Paris Saint-Joseph
      2022   Phase 2   EUCTR2022-002464-75-FR   France
Privigen 100MG/ML
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2018   Phase 3   EUCTR2018-002632-24-FR   France
PRM-151
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2020-001429-30-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000791-38-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Türkiye;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
   Hoffmann-La Roche
      2021   Phase 3   NCT04594707   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United States
      2021   Phase 3   NCT04552899   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2015   Phase 2   NCT02550873   Belgium;Czech Republic;Czechia;Germany;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2011   Phase 1   NCT01254409   Netherlands;United States
   PROMEDIOR, INC.
      2015   Phase 2   EUCTR2014-004782-24-IT   Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Spain;United Kingdom;United States
   Promedior inc
      2015   -   EUCTR2014-004782-24-NL   Netherlands
   Promedior, Inc.
      2016   Phase 2   EUCTR2014-004782-24-HU   Belgium;Czech Republic;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2016   Phase 2   EUCTR2014-004782-24-ES   Belgium;Czech Republic;Germany;Hungary;Netherlands;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2014-004782-24-DE   Belgium;Czech Republic;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2016   Phase 2   EUCTR2014-004782-24-CZ   Belgium;Czech Republic;France;Germany;Hungary;Netherlands;Spain;United Kingdom;United States
      2015   Phase 2   EUCTR2014-004782-24-BE   Belgium;Czech Republic;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Pulmonary rehabilitation program
   Boehringer Ingelheim
      2018   Phase 4   NCT03717012   United States
QAX576
   Novartis Pharma Services AG
      2011   -   EUCTR2010-020688-18-GB   United Kingdom
   Novartis Pharmaceuticals
      2010   Phase 2   NCT01266135   United Kingdom;United States
      2007   Phase 2   NCT00532233   United States
Recombinant human pentraxin-2
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2020-001429-30-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000791-38-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Türkiye;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
Regend001
   Regend Therapeutics
      2023   Phase 2   NCT06081621   China
      2021   Phase 1   NCT05657184   China
Remicade
   Academic Medical Centre
      2007   Phase 2   EUCTR2004-001876-37-DE   Germany
Revatio 20 MG
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2016   Phase 3   EUCTR2015-002619-14-IT   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim España, S.A.
      2016   Phase 3   EUCTR2015-002619-14-ES   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim France
      2017   Phase 3   EUCTR2015-002619-14-FR   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim Limited
      2016   Phase 3   EUCTR2015-002619-14-GB   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2016   Phase 3   EUCTR2015-002619-14-DE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 3   EUCTR2015-002619-14-BE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
Rituximab
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States
   University of Alabama at Birmingham
      2014   Phase 2   NCT01969409   United States
Rixathon 500 MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2018   Phase 3   EUCTR2018-002632-24-FR   France
RO 47-0203
   ACTELION PHARMACEUTICALS LTD
      2007   Phase 3   EUCTR2006-001183-24-SK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-IE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-001183-24-GB   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-001183-24-ES   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-DK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-DE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-CZ   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-AT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2006   -   EUCTR2006-001183-24-BE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      -   Phase 3   EUCTR2006-001183-24-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
   Actelion Pharmaceuticals Ltd
      2009   -   EUCTR2007-001741-18-AT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-NL   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-001741-18-GB   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-001741-18-FR   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-ES   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-DE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-CZ   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-BE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
RO0220912
   F. HOFFMANN - LA ROCHE LTD.
      2016   Phase 2   EUCTR2015-005131-40-IT   Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2015   Phase 4   EUCTR2015-003280-11-IT   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
   F. Hoffmann-La Roche Ltd
      2017   Phase 2   EUCTR2015-005131-40-HU   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2017   Phase 2   EUCTR2015-005131-40-CZ   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-NL   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-GR   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-ES   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-DE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-BE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 4   EUCTR2015-003280-11-NL   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2016   Phase 4   EUCTR2015-003280-11-DK   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2016   Phase 4   EUCTR2015-003280-11-DE   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
      2014   Phase 2   EUCTR2013-001163-24-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-PL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
   Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
      2015   Phase 4   EUCTR2015-003280-11-ES   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States
RO0280296
   F. Hoffmann-La Roche Ltd
      2017   Phase 2   EUCTR2015-005131-40-HU   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2017   Phase 2   EUCTR2015-005131-40-CZ   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-NL   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-GR   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-ES   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-DE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-BE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
RO5490255/F01-02
   F. Hoffmann-La Roche Ltd
      2014   Phase 2   EUCTR2013-001163-24-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-PL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-ES   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
RO7490677
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2020-001429-30-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000791-38-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
RO7490677 160 MG/8 ML
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
RO7490677 160 MG/8ML
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000791-38-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
RO7490677 160MG/8ML
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
RO7490677/ F01-02
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
RO7490677/F01-01
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
RO7490677/F01-02
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
RO7490677/F01-03
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-001429-30-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
Routine steroid administration group
   Yonsei University
      2021   -   NCT04996303   Korea, Republic of
RSN0402 part 1
   Shenzhen Resproly Biopharmaceutical Co., Ltd
      2024   Phase 1   NCT06482190   Australia
RSN0402 part 2
   Shenzhen Resproly Biopharmaceutical Co., Ltd
      2024   Phase 1   NCT06482190   Australia
RVT-1601
   Respivant Sciences GmbH
      2019   Phase 2   NCT03864328   Australia;Belgium;Canada;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-NL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-GB   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-DE   Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-BE   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
   Respivant Sciences, GmbH
      2019   Phase 2   EUCTR2018-004447-23-IT   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
RXC007
   Redx Pharma Plc
      2022   Phase 2   NCT05570058   Austria;Belgium;Czechia;Hungary;Italy;Poland;Spain;Switzerland;United Kingdom;United States
      2021   Phase 1   NCT04931147   United Kingdom
RXC007 20 MG capsule
   Redx Pharma Ltd.
      2023   Phase 2   EUCTR2022-000498-15-PL   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
   Redx Pharma Plc
      2023   Phase 2   EUCTR2022-000498-15-HU   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2022-000498-15-AT   Austria;Belgium;Czech Republic;Czechia;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2022-000498-15-CZ   Austria;Belgium;Czech Republic;Czechia;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
   Redx Pharma plc
      2022   Phase 2   EUCTR2022-000498-15-IT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
RXC007 50 MG capsule
   Redx Pharma Ltd.
      2023   Phase 2   EUCTR2022-000498-15-PL   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
   Redx Pharma Plc
      2023   Phase 2   EUCTR2022-000498-15-HU   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2022-000498-15-AT   Austria;Belgium;Czech Republic;Czechia;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2022-000498-15-CZ   Austria;Belgium;Czech Republic;Czechia;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
   Redx Pharma plc
      2022   Phase 2   EUCTR2022-000498-15-IT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
Salbutamol
   Royal Brompton & Harefield NHS Foundation Trust
      2012   Phase 1   NCT01457261   United Kingdom
SAR100842
   Horizon Therapeutics Ireland DAC
      2022   Phase 2   EUCTR2021-001253-32-NL   Argentina;Australia;Canada;Chile;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;United States
      2022   Phase 2   EUCTR2021-001253-32-GR   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001253-32-FR   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001253-32-ES   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
SAR156597
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2015   Phase 2   EUCTR2014-003933-24-IT   Czech Republic;Denmark;France;Germany;Greece;Italy;Portugal;Spain;United Kingdom
   Sanofi
      2015   Phase 2   NCT02345070   Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States
      2012   Phase 1/Phase 2   NCT01529853   Belgium;Canada;Chile;Mexico;Spain;United States
   sanofi-aventis recherche & développement
      2016   Phase 2   EUCTR2014-003933-24-PT   Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-003933-24-GR   Argentina;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-003933-24-GB   Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-003933-24-FR   Argentina;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-003933-24-ES   Argentina;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-003933-24-DK   Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-003933-24-DE   Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States
      2015   Phase 2   EUCTR2014-003933-24-CZ   Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States
Saracatinab
   National Jewish Health
      2020   Phase 1/Phase 2   NCT04598919   United States
SB17170
   SPARK Biopharma
      2025   Phase 2   NCT06747923   Korea, Republic of
SC1011
   Guangzhou JOYO Pharma Co., Ltd
      2023   Phase 2/Phase 3   NCT06125327   China
      2022   Phase 1   NCT06135363   China
Senicapoc
   Vejle Hospital
      2025   Phase 2   NCT06714123   Denmark;Estonia
Septrin
   Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)
      2013   Phase 3   EUCTR2012-005409-38-ES   Spain
   University of East Anglia
      2007   -   EUCTR2007-002324-15-GB   United Kingdom
SHR-1906
   Guangdong Hengrui Pharmaceutical Co., Ltd
      2023   Phase 2   NCT05722964   China
      2021   Phase 1   NCT04986540   China
Sildenafil
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2016   Phase 3   EUCTR2015-002619-14-IT   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim
      2016   Phase 3   NCT02802345   Australia;Belgium;Canada;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim España, S.A.
      2016   Phase 3   EUCTR2015-002619-14-ES   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim France
      2017   Phase 3   EUCTR2015-002619-14-FR   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim Limited
      2016   Phase 3   EUCTR2015-002619-14-GB   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2016   Phase 3   EUCTR2015-002619-14-DE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   F. HOFFMANN - LA ROCHE LTD.
      2016   Phase 2   EUCTR2015-005131-40-IT   Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
   F. Hoffmann-La Roche Ltd
      2017   Phase 2   EUCTR2015-005131-40-HU   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2017   Phase 2   EUCTR2015-005131-40-CZ   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-NL   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-GR   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-ES   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-DE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
      2016   Phase 2   EUCTR2015-005131-40-BE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
   Hoffmann-La Roche
      2016   Phase 2   NCT02951429   Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates
   National Heart, Lung, and Blood Institute (NHLBI)
      2004   Phase 2   NCT00352482   United States
   Rabin Medical Center
      2011   Phase 4   NCT01382368   Israel
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 3   EUCTR2015-002619-14-BE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States
   University of California, Los Angeles
      2007   Phase 4   NCT00625079   United States
   VA Office of Research and Development
      2006   Phase 2   NCT00359736   United States
Sildenafil and losartan
   Alicia Gerke
      2009   Phase 2/Phase 3   NCT00981747   United States
Sildenafil citrate
   Duke University
      2007   Phase 3   NCT00517933   United States
Simtuzumab
   Gilead Sciences
      2013   Phase 2   NCT01769196   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;United States
      2012   Phase 2   NCT01759511   United States
   Gilead Sciences, Inc.
      2013   -   EUCTR2012-001571-36-PL   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2013   -   EUCTR2012-001571-36-IT   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-001571-36-GB   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2013   -   EUCTR2012-001571-36-ES   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2013   -   EUCTR2012-001571-36-DE   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-001571-36-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2012-001571-36-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;United States
Sirolimus
   University of Virginia
      2011   -   NCT01462006   United States
Sivelestat
   Japanese Northern East Area Thoracic Surgery Study Group (JNETS)
      2013   Phase 3   JPRN-UMIN000021109   Japan
SM04646
   Samumed LLC
      1900   Phase 2   NCT03591926   Australia;New Zealand
Sodium cromoglicate
   Respivant Sciences GmbH
      2019   Phase 2   EUCTR2018-004447-23-NL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-GB   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-DE   Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004447-23-BE   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
   Respivant Sciences, GmbH
      2019   Phase 2   EUCTR2018-004447-23-IT   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States
SRN-001
   siRNAgen Therapeutics Inc.
      2023   Phase 1   NCT05984992   Australia
Sterile normal saline FOR intravenous USE
   Black Tie Medical, Inc.
      2020   Early Phase 1   NCT04326036   United States
Steroid pulse therapy group
   Yonsei University
      2021   -   NCT04996303   Korea, Republic of
SUB-study: nintedanib
   FibroGen
      2013   Phase 2   NCT01890265   Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States
SUB-study: pirfenidone
   FibroGen
      2013   Phase 2   NCT01890265   Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States
SUB03255MIG
   Groupe Hospitalier Paris Saint-Joseph
      2022   Phase 2   EUCTR2022-002464-75-FR   France
SUB10020MIG
   Groupe Hospitalier Paris Saint-Joseph
      2022   Phase 2   EUCTR2022-002464-75-FR   France
Sulfamethoxazole
   Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)
      2013   Phase 3   EUCTR2012-005409-38-ES   Spain
Sulphamethoxazole
   Norfolk and Norwich University Hospital NHS Foundation Trust
      2014   Phase 3   EUCTR2014-004058-32-GB   United Kingdom
Suplatast
   Hiroshima University Hospital, Department of Respiratory Medicine
      2008   Phase 3   JPRN-UMIN000001567   Japan
   Melius Pharma AB
      2024   Phase 2   NCT05983471   India
SV001
   Shanghai Synvida Biotechnology Co.,Ltd.
      2024   Early Phase 1   NCT06267183   China
Symbicort
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada
Taladegib
   Endeavor Biomedicines, Inc.
      2023   Phase 1   NCT05817240   Australia
      2021   Phase 2   NCT04968574   Australia;Canada;Korea, Republic of;Malaysia;Mexico
Tazarotene
   GRI Bio Operations, Inc.
      2024   Phase 2   NCT06331624   Australia;United Kingdom;United States
TBC
   Nitto Denko Corporation
      2018   Phase 2   EUCTR2017-004919-39-DE   Germany;Japan;United Kingdom;United States
TD-1058
   Theravance Biopharma
      2020   Phase 1   NCT04589260   United Kingdom
TD139
   Galecto Biotech AB
      2020   Phase 2   EUCTR2018-002664-73-IE   Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002664-73-PL   Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002664-73-IT   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002664-73-GB   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002664-73-FR   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002664-73-ES   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
TDI01 suspension
   Beijing Tide Pharmaceutical Co., Ltd
      2023   Phase 2   NCT06102083   -
   Chinese PLA General Hospital
      2023   Phase 1   ChiCTR2300071134   China
Tetrathiomolybdate
   University of Michigan
      2003   Phase 1/Phase 2   NCT00189176   United States
Thalidomide
   Johns Hopkins University
      2007   Phase 3   NCT00600028   United States
      2003   Phase 2   NCT00162760   United States
Thalidomide pharmion
   University of Nottingham
      2011   -   EUCTR2010-023828-24-GB   United Kingdom
THE standard steroid treatment, plasma exchange and rituximab
   University of Pittsburgh
      2012   Phase 2   NCT01524068   United States
Thiotepa
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States
Thrombomodulin alfa
   ASAHI KASEI PHARMA CORPORATION
      2016   Phase 3   JPRN-jRCT2080223271   Japan
Tiotropium
   Saitama Medical University
      2009   -   JPRN-UMIN000005793   Japan
Tipelukast
   MediciNova
      2016   Phase 2   NCT02503657   United States
TNX-650, rhumab ANTI-IL13, AIL-13, MILR1444A
   F. Hoffmann-La Roche Ltd
      2014   Phase 2   EUCTR2013-001163-24-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-PL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-ES   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
      2013   Phase 2   EUCTR2013-001163-24-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States
TR0311
   Trevi Therapeutics, Inc.
      2019   Phase 2   EUCTR2018-004744-31-GB   United Kingdom
Tracleer
   ACTELION PHARMACEUTICALS LTD
      2007   Phase 3   EUCTR2006-001183-24-SK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-IE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-001183-24-GB   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-001183-24-ES   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-DK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-DE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-CZ   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2007   -   EUCTR2006-001183-24-AT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2006   -   EUCTR2006-001183-24-BE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      -   Phase 3   EUCTR2006-001183-24-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
   Actelion Pharmaceuticals LTD
      2006   -   EUCTR2006-001183-24-IT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
   Actelion Pharmaceuticals Ltd
      2009   -   EUCTR2007-001741-18-AT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-NL   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-001741-18-GB   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-001741-18-FR   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-ES   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-DE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-CZ   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-001741-18-BE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
   Actelion Registration Ltd
      2008   -   EUCTR2007-001741-18-IT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
   Royal Brompton and Harefield NHS Trust
      2007   -   EUCTR2007-001645-17-GB   United Kingdom
Tralokinumab
   MedImmune LLC
      2012   Phase 2   NCT01629667   Australia;Canada;Israel;Korea, Republic of;Peru;United States
Tralokinumab cohort 1
   AstraZeneca
      2014   Phase 2   NCT02036580   Japan
      2014   Phase 2   JPRN-jRCT2080222402   -
Tralokinumab cohort 2
   AstraZeneca
      2014   Phase 2   NCT02036580   Japan
      2014   Phase 2   JPRN-jRCT2080222402   -
Treprostinil
   Rajan Saggar
      2008   Phase 2   NCT00705133   United States
   UNITED THERAPEUTICS CORPORATION
      2022   Phase 3   EUCTR2021-005881-17-IT   Argentina;Australia;Belgium;Chile;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Peru;Spain;Taiwan;United Kingdom
Treprostinil sodium FOR inhalation
   Lung Biotechnology PBC
      2008   Phase 2   NCT00703339   United States
Treprostinil ultrasonic nebulizer
   United Therapeutics
      2022   Phase 3   NCT05255991   Argentina;Australia;Belgium;Chile;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Peru;Spain;Taiwan
      2022   Phase 3   NCT04905693   Argentina;Australia;Belgium;Canada;Chile;Denmark;France;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Peru;Spain;Taiwan;United States
      2021   Phase 3   NCT04708782   Cameroon;Canada;Chile;United States
Trimethoprim
   Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)
      2013   Phase 3   EUCTR2012-005409-38-ES   Spain
   Norfolk and Norwich University Hospital NHS Foundation Trust
      2014   Phase 3   EUCTR2014-004058-32-GB   United Kingdom
TRK-250
   Toray Industries, Inc
      2018   Phase 1   NCT03727802   United States
TTI-101
   Tvardi Therapeutics, Incorporated
      2023   Phase 2   NCT05671835   United States
Tyvaso® (treprostinil) inhalation solution, FOR oral inhalation USE
   UNITED THERAPEUTICS CORPORATION
      2023   Phase 3   EUCTR2021-005881-17-NL   Argentina;Australia;Belgium;Chile;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Peru;Spain;Taiwan
      2023   Phase 3   EUCTR2021-005881-17-BE   Argentina;Australia;Belgium;Chile;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Peru;Spain;Taiwan
      2022   Phase 3   EUCTR2021-005881-17-DK   Argentina;Australia;Belgium;Chile;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Peru;Spain;Taiwan
Untreated cohort
   Boehringer Ingelheim
      2019   -   NCT03958071   United States
Uromitexan
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2015   Phase 3   EUCTR2015-000492-27-FR   France
Valganciclovir
   Fernanda P Silveira, MD, MS
      2021   Phase 2   NCT05041426   United States
   Vanderbilt University Medical Center
      2018   Phase 1   NCT02871401   United States
VAY736
   Novartis Pharma AG
      2018   Phase 2   EUCTR2017-002667-17-IT   Canada;France;Germany;Ireland;Italy;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002667-17-IE   Canada;France;Germany;Ireland;Italy;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002667-17-GB   Canada;France;Germany;Ireland;Italy;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002667-17-FR   Canada;France;Germany;Ireland;Italy;United Kingdom;United States
      2018   Phase 2   EUCTR2017-002667-17-DE   Canada;France;Germany;Ireland;Italy;United Kingdom;United States
   Novartis Pharmaceuticals
      2017   Phase 2   NCT03287414   Canada;France;Germany;Ireland;Italy;United Kingdom;United States
Venetoclax
   University of Alabama at Birmingham
      2023   Early Phase 1   NCT05976217   United States
Vismodegib
   F. Hoffmann-La Roche Ltd.
      2014   -   EUCTR2014-000963-42-DE   Australia;Chile;France;Germany;Israel;Italy;Korea, Republic of;Mexico;New Zealand;Peru;Spain;United States
   Hoffmann-La Roche
      2016   Phase 1   NCT02648048   Germany;United States
      2014   Phase 2   NCT02168530   Australia;France;Germany;Israel;Korea, Republic of;Mexico;Peru;United States
Vixarelimab
   Genentech, Inc.
      2023   Phase 2   NCT05785624   Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;New Zealand;Poland;South Africa;Spain;Taiwan;United States
Volibris
   Gilead Sciences Incorporated
      2009   -   EUCTR2008-004405-34-IT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom
VRP700
   Verona Pharma plc
      2013   -   EUCTR2012-005794-31-GB   United Kingdom
VUM02 injection
   Wuhan Optics Valley Vcanbiopharma Co., Ltd.
      2024   Phase 1   NCT06230822   China
Warfarin
   Duke University
      2009   Phase 3   NCT00957242   United States
Water
   Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
      2024   Phase 1   ChiCTR2400079658   China
Zileuton
   University of Michigan
      2001   Phase 2   NCT00262405   United States
Zinc
   Cedars-Sinai Medical Center
      2025   Phase 2   NCT06567717   United States
Zinpentraxin alfa
   Hoffmann-La Roche
      2021   Phase 3   NCT04594707   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United States
      2021   Phase 3   NCT04552899   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
Zinpetraxin alfa
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Türkiye;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000791-38-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States
Ziritaxestat
   Galapagos NV
      2019   Phase 3   EUCTR2018-001406-29-HU   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2019   Phase 3   EUCTR2018-001405-87-GR   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001405-87-GB   Australia;Belgium;Brazil;Chile;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001405-87-DE   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001405-87-CZ   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001405-87-BE   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001406-29-PL   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States
      2018   Phase 3   EUCTR2018-001405-87-DK   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States
   Galapagos NV(ICCC;PPDSNBL)
      2020   Phase 3   JPRN-jRCT2080225268   Asia except Japan;Europe;Japan;North America
ZL-2102
   Zai Lab Pty. Ltd.
      2015   Phase 1   NCT02397005   Australia
ZSP1603
   Guangdong Raynovent Biotech Co., Ltd
      2021   Phase 1/Phase 2   NCT05119972   China
ZSP1603 12.5 MG
   Guangdong Zhongsheng Pharmaceutical Co., Ltd.
      2018   Phase 1   NCT03619616   China
ZSP1603 25 MG
   Guangdong Zhongsheng Pharmaceutical Co., Ltd.
      2018   Phase 1   NCT03619616   China
ZSP1603 50 MG
   Guangdong Zhongsheng Pharmaceutical Co., Ltd.
      2018   Phase 1   NCT03619616   China
ZSP1603 7.5 MG
   Guangdong Zhongsheng Pharmaceutical Co., Ltd.
      2018   Phase 1   NCT03619616   China